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Since	the	1970s,	when	the	era	of	genome-editing	technology	began	with	the	
introduction	of	recombinant	DNA,	a	lot	of	research	conducted	in	labs	transitions	into	practical	
applications	that	consumers	see	on	the	market.	The	recent	discovery	of	Clustered	Regularly	
Interspaced	Short	Palindromic	Repeats	(CRISPR),	a	new	genome-editing	tool,	is	disrupting	
genome-editing	technology’s	path	to	commercialization.	This	thesis	aims	to	address	the	lessons	
learned	from	the	case	study	of	the	Flavr	Savr	tomato,	the	first	commercialized	food	product	in	
the	U.S.,	and	how	those	lessons	provide	insight	to	the	implications	of	commercially	using	
CRISPR.	Then,	more	broadly,	this	examination	analyzes	how	awareness	of	CRISPR’s	complexities	
and	the	intersection	between	science	and	business	suggests	that	commercialization	of	genome-
editing	technology	needs	to	be	more	efficient	in	the	evolving	landscape	of	genome	editing.		
The	first	task	is	to	understand	the	role	of	genome-editing	technology	in	establishing	the	
context	in	which	CRISPR	is	introduced.	The	second	task	involves	discussing	the	complexities	of	
using	CRISPR,	focusing	on	the	legal	and	ethical	implications.	The	third	task	is	to	compare	the	
case	study	of	the	CRISPR	application	in	sickle-cell	anemia	to	that	of	antisense	technology,	an	
earlier	discovered	genome-editing	technology,	application	in	the	Flavr	Savr	tomato.	Lastly,	this	
thesis	will	evaluate	the	impact	of	CRISPR’s	development	on	genome-editing	technology’s	
commercialization	path	and	put	forth	recommendations	on	how	to	bridge	some	of	the	
disconnect	between	science	and	business	in	order	to	make	the	commercialization	process	more	
efficient.		
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Introduction	
	
	 A	seemingly	small	change	can	lead	to	significantly	large	effects.	Take	for	example	
how	a	single	genetic	mutation	in	a	letter	of	DNA	can	lead	to	the	production	of	“sickle”-
shaped	red	blood	cells	and	result	in	fatal	consequences.	Or	consider	how	the	
implementation	of	a	new	tool	can	lead	to	treatments	for	genetic	diseases	and	a	
reduction	of	millions	of	dollars	in	research	and	development	costs.	These	situations	are	
applicable	to	and	all	too	familiar	in	the	realm	of	molecular	biology,	and	specifically	
genome	editing.	They	also	precisely	describe	the	phenomenon	of	The	Butterfly	Effect,	
which	captures	how	the	sensitivities	of	small	actions	are	magnified	to	large-scale,	
potentially	serious	implications.	In	genome	editing,	the	introduction	of	a	new	paradigm	
can	produce	unexpected	outcomes	due	to	insufficient	regulation	of	scientific	freedom	
within	the	lines	of	business	and	unclear	understanding	of	the	general	mechanisms	and	
potential	applications	of	genome-editing	technologies.	Those	outcomes	can	have	a	
significant	effect	when	they	translate	into	the	development	of	practical	applications,	
such	as	genetically-engineered	food	or	drugs	and	vaccines,	that	the	general	public	will	
be	exposed	to	on	a	regular	basis,	whether	we	are	aware	of	these	changes	or	not.					
Genome	editing,	a	type	of	genetic	engineering,	involves	inserting,	deleting,	or	
replacing	DNA	at	a	particular	location	in	an	organism’s	or	cell’s	genome.	It	is	often	
performed	in	the	lab	with	the	use	of	engineered	nucleases,	also	referred	to	as	molecular	
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scissors.1	Genome	editing	has	great	promise	for	application	in	a	variety	of	potential	
commercial	applications,	from	developing	anticancer	immunotherapies	to	producing	
biofuels.	The	versatility	of	genome	editing	has	made	it	a	“powerful	tool	in	basic	
biological	research.”2	The	genetic	engineering	age	began	in	the	1970s	when	Herbert	
Boyer	of	Stanford	University	and	Stanley	Cohen	of	the	University	of	California,	San	
Francisco	(UCSF)	developed	the	technique	to	recombine	the	genes	in	bacterial	plasmids	
–	this	technique	is	known	as	recombinant	DNA	technology.3,4		
In	the	late	1970s,	Genentech,	Boyer’s	biotechnology	company,	applied	the	
recombinant	DNA	technology	to	modify	E.	coli	to	contain	a	synthetic	human	gene.	In	the	
lab,	the	genetically	engineered	E.	coli	was	then	used	to	produce	insulin	for	diabetics.	
This	early	move	of	transitioning	genome-editing	technology	from	research	labs	into	the	
commercial	sector	demonstrated	the	potential	that	the	benefits	of	science	could	extend	
beyond	research	in	the	lab	to	the	reaches	of	our	communities.	Take	for	instance	the	
discovery	of	DNA’s	structure	–	the	research	on	DNA’s	structure	has	helped	to	create	
tests	that	detect	genetic	diseases	and	has	even	made	DNA	fingerprinting	an	
instrumental	technique	in	forensic	testing.	Technology	commercialization	is,	in	principle,	
																																																						
1	Gene	Editing		
2	Egelie,	K.	J.,	Graff,	G.	D.,	Strand,	S.	P.,	&	Johansen,	B.	(2016,	October).	The	emerging	
patent	landscape	of	CRISPR-Cas	gene	editing	technology.		
3	Russo,	E.	(2003,	January).	Recombinant	DNA:	The	First	Report	|	The	Scientist	
Magazine(R).	
4	Knox,	M.	(2014,	December	1).	Is	the	Gene-Editing	Revolution	Finally	Here?		
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about	identifying	a	market	for	a	specific	technology.5	In	the	case	of	commercializing	
genome-editing	technology,	the	process	relies	on	the	ability	to	efficiently	move	a	
product,	a	genome-editing	technology,	as	a	concept	from	the	lab	to	a	practical	
application	on	the	market.		
	 Making	observations	and	building	upon	them	to	conduct	research	and	ultimately	
make	predictions	and	discoveries	about	our	world	is	the	core	of	science.	The	vehicles	
that	help	drive	those	observations	and	predictions	forward	stem	from	the	use	of	
scientific	tools,	and	in	the	world	of	genome	editing,	we	have	various	technologies	to	
select	from,	including	zinc-finger	nucleases	(ZFNs),	transcription	activator-like	effector	
nucleases	(TALENs),	and	antisense	technology.		
In	the	1990s,	antisense	technology	was	used	to	create	the	Flavr	Savr	tomato,	the	
first	commercialized	food	product	in	the	U.S.	The	Flavr	Savr	tomato	case	used	antisense	
technology,	a	genome-editing	technology,	to	grow	the	fresh	tomato	market	–	I	will	
further	explore	the	case	in	this	thesis.	Among	the	current	genome-editing	technologies,	
Clustered	Regularly	Interspaced	Short	Palindromic	Repeats,	also	known	as	CRISPR,	is	the	
most	recently	introduced	“molecular	scissors”.	It	has	held	the	attraction	of	the	scientific	
world	and	is	attracting	the	investment	of	the	business	world.	
																																																						
5	Fletcher,	A.	C.,	&	Bourne,	P.	E.	(2012,	September	27).	Ten	Simple	Rules	to	
Commercialize	Scientific	Research.		
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In	this	thesis,	I	address	the	question:	how	do	the	lessons	from	the	use	of	
antisense	technology	in	the	Flavr	Savr	tomato	case	provide	insight	about	the	
implications	of	commercializing	CRISPR	today?	To	address	this	question,	I	will	first	
introduce	what	the	technology	is,	providing	a	general	explanation	of	its	mechanism	and	
characteristics.	Then	I	explore	the	complexities	of	CRISPR,	targeting	the	legal	and	ethical	
implications,	and	incorporating	personal	interview	responses	from	CRISPR	researchers	
to	better	inform	my	main	question.	Limitations	in	the	design	and	operation	of	past	
technologies	have	hindered	those	technologies	from	conquering	the	challenge	of	
precisely	editing	specific	DNA	sequences.	I	will	discuss	why	CRISPR	is	a	tool	that	holds	
the	potential	promise	of	addressing	that	challenge.	
I	then	undertake	a	case	study	of	CRISPR	in	sickle-cell	anemia	that	has	the	
potential	to	undergo	commercialization.	This	case	is	a	prime	candidate	to	explore	three	
implications	of	commercializing	CRISPR	I	will	address	in	this	thesis:	ethical	
considerations,	legal	considerations,	and	the	growing	disconnect	between	science	and	
business.	I	will	compare	this	CRISPR	study	to	that	of	an	antisense	technology	study	
based	on	the	Flavr	Savr	tomato	by	critically	examining	the	three	factors	mentioned	
above.			
I	conclude	by	offering	recommendations	on	how	we	can	more	efficiently	bridge	
the	disconnect	between	science	and	business	in	order	to	establish	an	ethically	mindful	
context	in	which	everyone,	including	the	general	public,	understands	the	significance	
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and	implications	of	CRISPR	as	well	as	that	of	genome-editing	technology.	The	realms	of	
science	and	business	have	clashing	values	and	practices,	and	these	differences	are	most	
apparent	when	the	two	realms	intersect	and	seek	to	collaborate.	As	science	and	
business	interact	to	enable	CRISPR	to	solve	real	world	problems,	we	need	to	determine	
how	to	better	manage	the	business	of	science.		
In	this	thesis,	I	discuss	only	one	of	CRISPR’s	paths	to	commercialization,	though	
there	may	be	many	different	paths.	Many	genome-editing	technologies	started	from	
industry,	but	academic	research	institutions	pioneered	CRISPR.6	Academic	research	
institutions	have	different	resources	and	access	to	business	expertise	to	commercialize	
genome-editing	technologies	compared	to	those	found	in	industry.	In	academia,	
research	can	be	valuable,	yet	after	publication	of	research	results,	that	value	may	only	
be	of	interest	to	other	scientists	within	the	same	field.	Whereas	in	industry,	there	can	be	
tangible	results	from	the	research	in	the	form	of	new	products	or	applications	that	have	
plans	to	be	commercialized	to	benefit	the	public	in	some	way.	CRISPR	biotechnology	
companies,	including	Caribou	Biosciences	and	Editas	Medicine,	started	out	of	academic	
institutions,	where	there	is	competition	to	commercialize	CRISPR.	So	to	explore	the	
complexities	of	commercializing	this	technology,	including	the	legal	implications	of	this	
																																																						
6	Brinegar,	K.,	Yetisen,	A.	K.,	Choi,	S.,	Vallillo,	E.,	Ruiz-Esparza,	G.	U.,	Prabhakar,	A.	M.,	...	
Yun,	S.	(2017).	The	commercialization	of	genome-editing	technologies.	Critical	Reviews	
in	Biotechnology,	1-12.	doi:10.1080/07388551.2016.1271768	
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competition,	my	focus	is	to	explore	the	commercialization	of	CRISPR	originating	from	
academic	institutions.	
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CRISPR	–	The	Duality	of	Molecular	Scissors	
	
	CRISPR,	“the	disruptor,”	as	a	Nature	article7	labels	this	technology,	is	being	
applied	across	a	variety	of	industries,	from	agriculture	to	animal	disease	models	that	
aim	to	prevent	and	treat	genetic	diseases,	such	as	sickle-cell	anemia.	The	acronym	
CRISPR	is	short	for	Clustered	Regularly	Interspaced	Short	Palindromic	Repeats,	
describing	the	organization	of	short,	partially	palindromic	repeated	DNA	sequences	that	
are	unique	and	separated	by	random	DNA	sequences.8	Among	the	excitement	
surrounding	the	growing	number	of	CRISPR	studies	and	publications	from	research	labs	
around	the	world,	it	is	easy	to	overlook	this	technology’s	origins.		
CRISPR	sequences	stem	from	a	natural	process	–	they	are	an	essential	
component	of	bacteria’s	immune	defense	system.	In	a	bacterial	cell,	the	CRISPR-based	
immune	system	works	in	three	basic	steps:	1)	Adaptation	–	when	a	new	virus	attacks	a	
bacterial	cell,	a	part	of	the	virus,	a	spacer,	is	derived	and	combined	into	the	bacterial	
cell’s	CRISPR	sequence.	This	step	allows	the	bacterial	cell	to	record	the	“memory”	of	the	
virus	attacking.	2)	Production	of	CRISPR	RNA	molecules	–	the	CRISPR	sequence	with	the	
newly	incorporated	viral	DNA	sequence	is	transcribed	to	produce	molecules	of	CRISPR	
																																																						
7	Ledford,	H.	(2015,	June	08).	CRISPR,	the	disruptor.	Nature,	522(7554),	20-24.	
doi:10.1038/522020a	
8	Pak,	E.	CRISPR:	A	game-changing	genetic	engineering	technique	-	Science	in	the	
News.		
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RNA.	The	CRISPR	RNA	matches	the	viral	DNA	sequence	exactly.	3)	Targeting	–	when	the	
same	type	of	virus	attacks	the	bacterial	cell	in	the	future,	then	these	CRISPR	RNAs	guide	
the	bacterial	cell’s	molecular	machinery,	a	nuclease	like	Cas9,	to	the	matching	sequence	
in	the	invading	virus	so	that	Cas9	can	identify,	then	cut,	and	ultimately	destroy	the	virus.			
See	Figure	1	for	the	timeline	of	CRISPR	events.	The	CRISPR	story	started	in	1987,	
when	researchers	in	Japan	found	a	“series	of	repeated	stretches…interrupted	by	unique	
‘spacer’	sequences.”9	The	mechanism	was	elucidated	over	the	next	10	years	as	more	
repeating	elements	were	observed	in	the	genomes	of	different	bacterial	strains.	In	2000,	
Mojica	et	al.	classified	the	interspaced	repeat	sequences	as	a	unique	group	of	clustered	
repeat	elements	in	bacteria,	and	not	long	after,	in	2002,	the	CRISPR	acronym	was	
adopted.		
Only	recently,	in	2012,	did	it	become	clear	that	the	CRISPR	technology	can	be	
applied	in	genome	editing.	Jennifer	Doudna	and	Emmanuelle	Charpentier	realized	that	
bacteria’s	CRISPR	immune	defense	system	has	the	potential	to	edit	human	genes	or	
those	of	any	other	organism.	In	a	Science	paper	published	in	June	2012,	Doudna,	an	
American	RNA	biologist,	and	Charpentier,	a	French	microbiologist,	showed	site-specific	
DNA	cleavage	for	the	first	time	when	using	the	Cas9	protein	in	vitro.	They	believe	“the	
potential	for	CRISPR	applications…will	affect	almost	every	aspect	of	life,	and	provide	
																																																						
9		Fitzpatrick	Dimond,	P.	F.	(2013,	November	8).	CRISPR	Madness.		
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inspiration	for	future	technological	breakthroughs.”10	Still,	it	wasn’t	until	January	2013	
when	Feng	Zhang,	MIT	bioengineer,	developed	a	new	version	of	CRISPR-Cas9	and	
directly	performed	gene	editing	in	human	cells.		
	
Figure	1	from	Nature	Biotechnology	(2016)	34:1025	
																																																						
10	Egelie,	K.	J.,	Graff,	G.	D.,	Strand,	S.	P.,	&	Johansen,	B.	(2016,	October).	The	emerging	
patent	landscape	of	CRISPR-Cas	gene	editing	technology.		
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In	2012,	as	more	of	the	scientific	community	learned	about	CRISPR,	this	nascent	
technology	was	welcomed	into	labs	around	the	world	and	researchers	began	to	alter	
genes.	In	contrast	to	ZFNs	and	TALENs,	CRISPR	is	considered	to	be	easier	and	faster	to	
use,	more	accessible,	and	cheaper.7				
	
“CRISPR	is	the	Model	T	of	genetics,”	says	Hank	Greely,	a	professor	at	Stanford	
Law	School	and	the	director	of	the	Center	for	Law	and	the	Biosciences.	“The	
Model	T	wasn’t	the	first	car,	but	it	changed	the	way	we	drive,	work,	and	live.	
CRISPR	has	made	a	difficult	process	cheap	and	reliable.	It’s	incredibly	precise.	But	
an	important	part	of	the	history	of	molecular	biology	is	the	history	of	editing	
genes.”11		
	
CRISPR’s	introduction	is	gaining	popularity	in	the	realm	of	molecular	biology;	
however,	a	tool	that	is	easy	to	use	is	also	one	that	is	easy	to	abuse.	The	duality	of	the	
CRISPR	technology	is	subtle	but	necessary	to	address	when	considering	the	complexities	
of	this	tool.		
	
	
	
																																																						
11		Specter,	M.	(2015,	November	16).	The	Gene	Hackers.		
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Legal	and	Ethical	Implications	of	CRISPR	
	
	 In	order	to	fully	comprehend	the	significance	of	CRISPR’s	role	in	revolutionizing	
genome-editing	technology’s	transition	from	academic	research	into	commercialized	
products,	I	will	focus	on	and	deconstruct	two	main	complexities.	The	first	complexity	
concerns	the	legal	implications	I	will	explore	through	the	question	how	does	the	CRISPR	
patent	dispute	play	a	role	in	CRISPR’s	path	to	commercialization,	and	the	second	
complexity	involves	the	ethical	implications	guided	by	the	question	of	what	are	the	
current	ethical	guidelines	working	with	CRISPR.		
	
Legal	Implications	
The	battle	for	exclusive	scientific	rights	is	not	unusual	among	universities.	In	
1974,	Stanford	University	and	UCSF	applied	for	a	patent	on	Boyer	and	Cohen’s	
development	of	recombinant	DNA.	The	academic	institutions	received	the	patent	in	
1980.	However,	originally	universities	were	unable	to	receive	federal	funding	to	develop	
their	patented	inventions.	Once	the	Bayh-Dole	Act	of	1980	was	passed,	public	
universities	could	patent	federally	funded	research.	As	more	public	research	institutions	
began	seeking	patents	for	their	discoveries,	these	institutions	became	more	immersed	
in	the	commercialization	of	their	research.	Many	institutions	seek	patents	for	their	
discoveries	to	gain	exclusive	rights	to	commercially	use	and	exploit	the	invention	for	a	
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certain	period	of	time,	reducing	competition	from	other	institutions	that	also	want	to	
exploit	that	invention.	Additionally,	after	receiving	a	patent,	institutions	have	the	power	
to	sell	or	license	the	rights	to	others	as	a	source	of	income.12	The	CRISPR	patent	dispute	
between	UC	Berkeley	and	the	University	of	Vienna	vs.	the	Broad	Institute	of	MIT	and	
Harvard	University	is	the	most	recent	and	highly	discussed	example	of	leading	research	
institutions	competing	for	the	rights	to	own	and	develop	a	genome-editing	technology.	
This	patent	dispute	exhibits	how	patents	can	influence	the	ethical	implications	of	
utilizing	the	CRISPR	technology.		
Doudna	and	Charpentier’s	2012	paper	revealed	CRISPR’s	potential	as	a	gene-
editing	tool,	while	Feng	Zhang’s	2013	paper	demonstrated	that	he	took	Doudna	and	
Charpentier’s	finding	a	step	further	with	his	direct	application	of	CRISPR	in	human	cells.	
Zhang	ultimately	demonstrated	that	CRISPR	is	an	efficient	way	of	editing	any	organism’s	
genome.	Both	groups	recognized	the	promising	possibilities	of	their	discoveries,	and	so	
UC	Berkeley	and	the	University	of	Vienna,	the	respective	institutions	that	Doudna	and	
Charpentier	are	affiliated	with,	and	the	Broad	Institute	at	MIT	and	Harvard	University,	
where	Zhang	is,	filed	patent	applications	for	their	work.			
	 In	late	2012,	UC	Berkeley	and	the	University	of	Vienna	filed	a	U.S.	patent	
application	through	the	U.S.	Patent	and	Trademark	Office	(USPTO)	together,	while	the	
Broad	Institute	at	MIT	and	Harvard	University	filed	their	first	patent	application	a	few	
																																																						
12	Reasons	for	Patenting	Your	Inventions.	
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months	later.	Although	Doudna’s	team	filed	first,	Zhang’s	team	fast	tracked	their	
application.	Consequently,	in	April	2014,	the	Broad	Institute	at	MIT	and	Harvard	
University	were	granted	U.S.	patents.	To	counter	this	result,	UC	Berkeley	filed	an	
interference	proceedings	request	to	the	USPTO	in	April	2015,	providing	the	argument	
that	Doudna	and	Charpentier	were	first	to	discover	the	aspects	of	CRISPR	that	were	
included	in	the	granted	patent	to	Zhang	and	his	team	at	the	Broad	Institute	and	Harvard	
University.		
In	February	2017,	judges	at	the	USPTO	confirmed	that	Zhang’s	work	on	living	
animal	and	plant	cells	was	original	work	that	deserved	patent	protection.	So	the	USPTO	
ruled	that	Zhang,	the	Broad	Institute,	and	Harvard	University’s	patents	concerning	
editing	eukaryotic	genomes	with	the	CRISPR	technology	did	not	interfere	with	the	claims	
UC	Berkeley	and	the	University	of	Vienna	filed.	The	East	Coast	institutions	were	
victorious	in	keeping	their	CRISPR	patents	–	Zhang	expressed	relief	that	he	could	finally	
go	back	to	focusing	on	his	research.		
	 Doudna	and	Charpentier	still	received	patents	on	their	original	work	on	CRISPR.	
However,	the	patent	outcome	was	based	partly	on	Doudna’s	comments	when	she	
voiced	her	uncertainty	about	whether	CRISPR	would	work	in	cells	with	nuclei	–	Doudna	
fears	the	patent	ruling	could	make	“every	scientist	now	factor	in	a	potential	patenting	
strategy	and	alter	how	transparent	[he	is]	about	[his]	work.”	13	In	other	words,	this	ruling	
																																																						
13	Achenback,	J.	(2017,	February	17).	CRISPR	pioneer	muses	about	long	journey	from	
China	to	pinnacle	of	American	science.		
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could	result	in	less	transparency	in	scientific	communication	as	scientists	withhold	
information	or	mask	their	uncertainties	in	their	research	in	order	to	attain	patents.		
	 Both	parties	of	the	patent	dispute	have	created	companies	co-founded	by	their	
researchers:	UC	Berkeley	and	Doudna	co-founded	Caribou	Biosciences	and	the	Broad	
Institute	at	MIT	and	Zhang	co-founded	Editas	Medicine.	In	addition	to	the	financial	
investments	in	these	biotechnology	companies,	the	CRISPR	patents	are	believed	to	be	
worth	hundreds	of	millions,	and	possibly	billions	of	dollars.14	Commercial	agreements	
with	agricultural	and	biomedical	companies	are	tied	up	with	billions	of	dollars	at	stake.	
For	example,	DuPont	Pioneer,	a	large	seed	producer	for	agriculture,	and	Caribou	
Biosciences	have	entered	into	a	strategic	alliance	to	use	CRISPR	with	the	same	or	fewer	
resources	to	produce	higher-yielding	crops,	while	Vertex	Pharmaceuticals,	a	drug	
company,	and	CRISPR	Therapeutics	have	entered	into	a	$2.6	billion	agreement	to	
develop	treatments	for	genetic	diseases	like	sickle-cell	anemia	and	cystic	fibrosis.15	Both	
parties	of	the	dispute	retained	their	patents,	so	companies	that	had	entered	into	
commercial	agreements	with	either	of	the	two	parties	face	uncertainty	regarding	
whether	they	have	to	attain	licenses	from	both	parties	in	order	to	utilize	the	CRISPR	
technology	in	eukaryotic	cells.16		
																																																						
14	Sherkow,	J.	S.	(2016,	April	14).	CRISPR:	Pursuit	of	profit	poisons	collaboration.	Nature,	
532,	172-173.	doi:10.1038/532172a	
15	CRISPR	Commercialization	Risk.		
16	Ledford	H.	(2017,	February	23).	Broad	Institute	wins	bitter	battle	over	CRISPR	patents.	
Nature,	542,	401.	doi:10.1038/nature.2017.21502	
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	 The	bitter	CRISPR	patent	dispute	between	Doudna’s	and	Zhang’s	sides	has	been	
resolved,	but	going	forward	the	verdict	reveals	complex	questions	about	how	scientists	
should	communicate	to	others	about	their	CRISPR	research	and	the	licensing	steps	
companies	need	to	take	to	use	CRISPR	in	developing	practical	solutions	for	consumers.			
	
Ethical	Implications	
	
	 Researchers	have	high	hopes	that	the	CRISPR	technology	can	ameliorate	many	of	
the	challenges	that	the	life	sciences	face,	from	creating	hardier	plants	to	editing	human	
genes	in	order	to	eliminate	diseases.	Although	this	genome-editing	technology	has	a	lot	
to	offer,	its	safety	and	ethical	concerns	cannot	be	ignored.	Researchers	have	been	
struggling	to	establish	an	ethical	framework	in	regards	to	working	with	genome-editing	
technology	ever	since	the	1970s.	A	possible	explanation	for	this	struggle	is	the	vast	
number	and	complexity	of	ethical	questions	that	emerge	when	a	technology	is	
introduced.	When	researchers	do	not	fully	understand	the	intricacies	of	the	
technology’s	mechanisms,	we	cannot	anticipate	all	the	applications	and	potential	
ramifications	of	utilizing	it.	Consequently,	we	are	limited	in	our	ability	to	address	the	
large	quantity	of	difficult	ethical	questions	pertaining	to	the	use	of	the	genome-editing	
technology.	Additionally,	establishing	an	ethical	framework	involves	taking	individual	
interests	and	those	of	the	community	into	consideration;	however,	the	best	outcome	
for	one	individual	does	not	suggest	that	it	is	the	best	outcome	for	everyone.	Still,	by	
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grappling	with	the	various	difficult	ethical	questions,	we	can	strive	to	implement	ethical	
guidelines	that	account	for	everyone’s	best	interests	given	the	limitations	in	our	
knowledge	of	the	genome-editing	technology.		
From	interviews	I	conducted	with	CRISPR	scientists	at	MD	Anderson	Cancer	
Center,	I	identified	researchers’	limited	ethical	awareness	about	the	implications	of	their	
work.	The	limited	ethical	awareness	is	most	likely	the	result	of	researchers’	narrower	
scope	of	focus	in	better	understanding	the	mechanical	functions	of	a	genome-editing	
technology.	Researchers’	work	is	highly	technical,	where	researchers	are	immersed	in	
the	scientific	process	to	learn	more	about	the	technology’s	mechanisms.	Ethical	
questions	about	the	application	of	a	genome-editing	technology	tend	to	be	outside	the	
scope	of	the	research	lab,	so	researchers	often	do	not	have	the	time	to	focus	on	the	
ethical	issues	when	researchers’	priorities	are	more	science	driven.	In	a	phone	interview	
with	Dr.		Lei	Li,	a	professor	of	cancer	research	who	is	conducting	CRISPR	research	at	MD	
Anderson,	when	asked	what	challenges	there	are	in	working	with	CRISPR,	his	response	
focused	on	the	technical	difficulties	of	using	the	technology.	Only	when	I	brought	up	the	
topic	of	social	and	ethical	implications	of	using	CRISPR	did	Dr.	Li	share	that	he	had	not	
considered	the	ethical	implications	before	because	all	of	his	research	and	the	research	
conducted	at	MD	Anderson	were	within	the	National	Institutes	of	Health	guidelines,	
involving	no	embryo	research.17	Additionally,	we	are	observing	evolving	attitudes	
																																																						
17	Li,	L.	(2016,	November	23).	Interview	with	CRISPR	Scientist	[Telephone	interview].	
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towards	the	science	enterprise	with	the	public’s	reticence	to	accept	genome-editing	
practices,	especially	those	involving	germline	editing,18	in	part	due	to	scientists’	failure	
to	effectively	communicate	information	about	the	technologies	with	nonscientists.		
Human	germline	editing	has	become	a	deeply	controversial	topic	when	exploring	
ethical	implications	in	the	use	of	CRISPR	technology.	Germline	editing	involves	altering	
genes	that	can	be	transmitted	to	future	progeny.	Proponents	of	human	germline	editing	
argue	that	it	might	decrease,	or	even	eliminate,	the	incidence	of	genetic	diseases	and	
consequently	diminish	human	suffering.	However,	most	recently,	this	type	of	
modification	sparked	unsettling	concerns	when	Chinese	researchers	reported	genome	
editing	of	human	embryos	to	correct	the	gene	mutations	responsible	for	beta-
thalassemia,	a	type	of	genetic	blood	disorder.	The	researchers’	experiment	was	
unsuccessful	–	only	a	small	fraction	of	the	CRISPR-edited	cells	in	the	embryos	contained	
the	corrected	genetic	material.	Nature	Biotechnology	interviewed	researchers,	business	
leaders,	and	ethicists	on	the	discussion	of	ethical	issues	of	human	germline	engineering	
with	CRISPR.	Emmanuelle	Charpentier’s	interview	response	emphasizes	that	safety	
concerns	are	potentially	the	most	significant	challenges	to	address.19	Though	she	did	not	
specify	what	those	safety	concerns	are,	based	on	context,	Charpentier	was	most	likely	
																																																						
18	Human	Genome	Editing:	Science,	Ethics,	and	Governance.	Rep.	The	National	
Academies	Press,	2017.	Web.	
19	Bosley,	K.	S.,	Botchan,	M.,	Bredenoord,	A.	L.,	Carroll,	D.,	Charo,	R.	A.,	Charpentier,	
E.,	...	Corn,	J.	(2015).	CRISPR	germline	engineering	-	the	community	speaks.	Nature	
Biotechnology,	33,	478-486.	doi:10.1038/nbt.3227	
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referring	to	the	premature	use	or	misuse	of	CRISPR	and	the	potential	off-target	effects	
of	using	this	technology.	Other	researchers,	business	leaders,	and	ethicists	also	cited	
these	same	safety	concerns	in	their	interviews.		
Off-target	effects	are	not	unique	to	CRISPR.	There	are	varying	levels	of	off-target	
activity	depending	on	the	target	sequence	that	needs	to	be	edited,	but	off-target	effects	
caused	by	the	use	of	CRISPR	are	“significantly	lower”	compared	to	those	of	other	gene	
therapy	strategies	that	use	viral	vectors.20	Viral	vectors	are	less	precise,	potentially	
randomly	integrating	into	the	genome	to	perform	unintended	edits.	In	contrast,	CRISPR	
uses	an	engineered	nuclease	and	precise	RNA-guided	system	where	the	guide	RNA	
“guides”	the	engineered	nuclease	to	the	target	site	in	the	genome	where	the	
engineered	nuclease	makes	the	intended	edit.	Despite	CRISPR’s	relative	precision,	
currently	no	genome-editing	technology	is	completely	error-free,	including	CRISPR,	so	
off-target	effects	may	still	occur	and	affect	other	genes’	functions,	possible	causing	
other	unexpected	diseases.	In	the	case	of	the	single-gene	mutation	that	causes	sickle-
cell	anemia,	using	CRISPR	could	cause	off-target	effects	that,	instead	of	correcting	for	
that	mutation,	could	lead	to	beta-thalassemia,	another	type	of	blood	disorder.		
After	a	group	of	Chinese	researchers	published	their	unsuccessful	results	with	
germline	editing	of	human	embryos	using	CRISPR	in	early	2015,	the	U.S.	National	
Academy	of	Sciences,	the	U.S.	National	Academy	of	Medicine,	the	UK	Royal	Society,	and	
																																																						
20	Ibid.	
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the	Chinese	Academy	of	Sciences	organized	the	International	Summit	on	Human	Gene	
Editing.	In	December	2015,	nearly	500	ethicists,	scientists,	legal	experts,	and	advocacy	
groups	worldwide	gathered	in	Washington	D.C.	for	the	summit.	Thoughtful	discussion	
on	the	prospect	of	human	genome	editing	at	this	summit	concluded	with	the	organizing	
committee,	composed	of	12	physicians,	bioethicists,	and	biologists,	strongly	endorsing	
the	use	of	CRISPR	in	germline	editing;	however,	they	agreed	that	this	application	of	
CRISPR	is	currently	“irresponsible	because	of	ongoing	safety	concerns	and	a	lack	of	
societal	consensus”.21	These	ongoing	safety	concerns	pertain	specifically	to	off-target	
effects	and	although	a	consensus	across	societies	seems	unrealistic,	since	each	nation	
has	its	own	perspectives	based	on	its	respective	cultural,	social,	and	political	situation,	
the	international	community	should	aim	to	create	general	guidelines.	These	general	
guidelines	will	then	allow	countries	to	create	their	own	national	regulatory	policies	that	
abide	by	those	general	guidelines.	Establishing	national	regulations	and	norms	about	
acceptable	uses	of	genome-editing	technologies	can	help	to	discourage	unacceptable	
applications	of	these	technologies.		
This	2015	conference	has	been	compared	to	the	1975	Asilomar	Conference,	
where	a	group	of	approximately	140	participants,	including	scientists,	lawyers,	
journalists,	and	government	officials,	had	convened	to	discuss	the	technique	and	
																																																						
21	Travis,	J.	(2015,	December	4).	Inside	the	summit	on	human	gene	editing:	A	reporter's	
notebook.		
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implications	of	utilizing	recombinant	DNA.22	Before	the	conference,	scientists	had	called	
for	a	moratorium	on	recombinant	DNA	research,	but	at	the	conference,	the	moratorium	
was	relaxed	–	it	was	decided	that	after	assigning	a	risk	estimate	to	each	type	of	lab	
experiment	that	could	be	conducted	with	recombinant	DNA,	labs	could	better	ensure	
lab	safety	while	using	this	technology.	As	a	result,	recombinant	DNA	research	in	labs	
continued.	The	1975	conference	on	recombinant	DNA	opened	the	discussion	about	
science	policy,	just	as	the	2015	summit	did,	yet	some	people	argue	that	the	Asilomar	
conference	was	distinct.		
David	Baltimore,	who	was	present	at	the	Asilomar	conference	and	was	chair	of	
the	organizing	committee	at	the	summit	on	gene-editing,	highlighted	the	difference	
between	the	Asilomar	conference	and	the	summit	on	human	gene	editing.	Biosafety	
concerns	about	lab	experiments	using	recombinant	DNA	motivated	the	1975	
conference,	whereas	ethical	concerns	about	the	safety	of	utilizing	CRISPR	in	treating	
humans	motivated	the	2015	summit.22	The	current	issues	with	genome-editing	
introduce	more	heterogeneous	concerns	that	extend	beyond	questions	on	safe	lab	use	
of	genome-editing	technologies.	Especially	since	CRISPR	is	the	most	advanced	genome-
editing	technology	we	know	of	and	is	touted	to	be	faster,	cheaper,	and	easier	to	use	
compared	to	zinc-finger	nucleases	(ZFNs)	and	transcription	activator-like	effector	
																																																						
22	Berg,	P.	(2008,	September	17).	Meetings	that	changed	the	world:	Asilomar	1975:	DNA	
modification	secured.		
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nucleases	(TALENs),	heterogeneous	concerns	include	questions	about	the	scope	of	
application	of	these	technologies	and	who	can	benefit	from	those	applications,	for	
example.			
In	early	2017,	the	National	Academy	of	Sciences	published	an	updated	ethics	
report	on	the	use	of	genome-editing	technologies,	specifically	discussing	CRISPR.23	This	
new	report	expresses	a	more	permissive	position	towards	germline	editing	–	it	suggests	
proceeding	with	caution	but	not	entirely	prohibiting	germline	editing	to	potentially	treat	
certain	rare	diseases.	There	is	slightly	more	leniency	towards	the	use	of	CRISPR	in	this	
new	report	compared	to	the	2015	summit	decision	where	the	organizing	committee	
believed	it	would	be	irresponsible	to	go	forward	with	germline	editing	at	the	present	
time.24			
	 The	extensive	ethics	report	from	the	National	Academy	of	Sciences	provides	
current	ethical	guidelines	for	genome	editing	in	basic	science	lab	research,	clinical	uses	
of	somatic	cell	editing,	and	germline	editing.	Establishing	ethical	guidelines	on	the	use	of	
genome-editing	technology	like	CRISPR	is	not	a	simple	task.	These	ethical	guidelines	
support	us	in	making	decisions	that	uphold	the	standards	of	behavior	within	a	given	
society.	Different	countries	have	varying	opinions	of	what	constitutes	“right”	and	
																																																						
23	Human	Genome	Editing:	Science,	Ethics,	and	Governance.	(2017).		
24	Achenbach,	J.	(2017,	February	14).	Ethicists	advise	caution	in	applying	CRISPR	gene	
editing	to	humans.		
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“wrong”	behavior,	significantly	influenced	by	each	country’s	cultural,	social,	and	political	
background.	Even	within	the	U.S.,	the	diversity	of	stakeholders,	comprised	of	scientists,	
business	professionals,	the	general	public,	inter	alia,	means	there	are	a	variety	of	goals	
the	stakeholders	have	that	ethical	guidelines	should	aim	to	address.	For	example,	
scientists	aim	to	analyze	the	patterns	from	genetic	data	and	animal	models	to	better	
understand	and	discover	more	about	the	mechanisms	of	genome-editing	technologies.	
Business	professionals	strive	to	invest	in	genome-editing	technologies	that	have	an	
economic	incentive	to	be	commercialized	or	to	use	and	develop	applications	for	
consumers	within	healthcare	or	agriculture,	for	instance.	Attempting	to	use	a	standard	
set	of	ethical	guidelines	to	help	all	stakeholders	achieve	their	personal	goals	is	not	a	
realistic	task,	but	we	can	endeavor	to	identify	general	guidelines	that	support	the	
harmonization	of	stakeholders’	values	and	goals.		
One	way	to	approach	developing	these	guidelines	is	to	draw	upon	ethical	
principles	that	are	often	based	on	philosophical	theories	–	for	instance,	deontologists	
may	view	some	acts	as	always	wrong,	even	if	the	outcome	is	beneficial.	From	a	
deontological	standpoint,	if	the	act	of	killing	and	editing	a	human	embryo	is	wrong,	even	
if	the	act	could	mean	future	prevention	of	more	embryo	deaths,	there	would	not	be	a	
justification	for	editing	the	embryo.	Utilitarians,	on	the	other	hand,	evaluate	whether	
the	outcome	is	beneficial	but	may	disagree	on	evaluating	the	consequences	of	a	specific	
act.	Therefore,	a	utilitarian	perspective	on	the	embryo	editing	example	would	favor	
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killing	and	editing	an	embryo	for	research	because	this	act	might	help	prevent	a	greater	
number	of	embryo	deaths	in	the	future.	These	two	philosophical	theories	are	just	a	few	
of	the	models	that	are	taken	into	consideration	in	an	effort	to	understand	what	
standards	of	behavior	are	considered	ethical.	Public	policy	enacted	to	address	the	
ethical	use	of	genome-editing	technologies	does	not	draw	upon	philosophical	theories	
necessarily.	However,	these	theories	can	present	to	us	the	potential	options	we	have	
when	making	ethical	decisions	in	situations	when	we	may	utilize	these	technologies,	for	
example	in	germline	editing	or	in	genetically-modified	organisms	(GMOs).		
Beyond	analyzing	individual	philosophical	theories,	there	should	also	be	a	focus	
on	approaching	the	ethical	guidelines	with	“reflective	equilibrium,”25	a	concept	
American	philosopher	John	Rawls	coined.	Reflective	equilibrium	gathers	a	wide	range	of	
theories	or	beliefs	about	an	issue	and	involves	reflecting	on	and	revising	those	beliefs	in	
order	to	find	a	general	coherence	and	understanding	among	the	comprehensiveness	of	
the	beliefs.	We	undergo	this	period	of	reflection	and	revision	of	beliefs,	testing	them	
against	each	other,	until	they	are	not	in	conflict	anymore	and	may	support	each	other.	
Once	our	beliefs	are	not	in	conflict	anymore,	or	are	in	equilibrium,	then	we	can	judge	
that	our	beliefs	are	morally	sound,	and	consequently	we	are	more	likely	to	adhere	to	
them.		
																																																						
25	Daniels,	N.	(2003,	April	28).	Reflective	Equilibrium.		
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In	applying	the	model	of	“reflective	equilibrium”	with	respect	to	CRISPR,	we	
would	first	need	to	include	both	scientists	and	nonscientists	in	a	discussion	about	the	
use	of	CRISPR.	With	both	groups	present	to	share	their	thoughts,	we	can	identify	various	
issues	and	beliefs	about	using	CRISPR	in	genome	editing.	Take	for	example,	the	issue	of	
germline	editing	using	CRISPR.	Some	scientists	may	believe	using	CRISPR	in	germline	
editing	is	inevitable,	while	some	individuals	from	the	nonscientific	group	may	be	weary	
of	using	CRISPR	in	germline	editing	because	of	the	fear	of	off-target	effects.	The	groups	
would	discuss	their	beliefs	and	test	them	out	to	determine	if	there	is	a	way	in	which	
both	beliefs	can	work	together	instead	of	being	in	conflict	with	each	another.	The	
discussion	may	revise	individuals’	original	beliefs	on	germline	editing	or	new	concerns	
may	surface.	This	process	of	reflection	and	revision	of	beliefs	may	yield	a	potential	
option	that	allows	the	two	beliefs	to	work	together:	contingent	on	certain	regulations,	
such	as	decreasing	the	risks	of	off-target	effects	to	a	safely	determined	level,	proceed	
cautiously	with	using	CRISPR	in	germline	editing.	With	the	two	groups’	beliefs	working	
together	to	form	this	general	consensus,	there’s	a	higher	likelihood	that	both	groups	
would	comply	to	this	option.	Although	identifying	a	coherent,	general	consensus	may	
not	be	possible	with	every	issue	regarding	the	use	of	CRISPR,	“reflective	equilibrium”	
can	at	least	help	to	identify	the	overarching	issues	that	people	have	about	using	CRISPR	
and	help	to	narrow	down	the	potential	options	for	next	steps.	We	still	do	not	
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understand	all	the	mechanisms	of	CRISPR	yet,	so	the	ethical	guidelines	need	to	be	able	
to	respond	and	adapt	to	new	discoveries	about	this	technology.	
After	exploring	the	legal	and	ethical	complexities	of	CRISPR	in	this	chapter,	the	
next	step	is	to	examine	the	application	of	this	technology	in	sickle-cell	anemia	and	how	
the	case	reflects	the	complexities	discussed	in	this	chapter.			
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Background	on	Sickle-Cell	Anemia	
	 Approximately	250,000	children	around	the	world	are	born	with	sickle-cell	
anemia	every	year.26	This	disorder	is	particularly	prevalent	in	African	Americans	and	
those	with	African	ancestry	and	is	the	most	common	and	often	most	severe	kind	of	
sickle-cell	disease.	Sickle-cell	anemia	is	a	recessively	inherited	blood	disorder	caused	by	
a	single	DNA	letter	genetic	mutation	that	leads	to	the	production	of	abnormal	
hemoglobin,	resulting	in	the	characteristic	“C”	or	“sickle”-shaped	red	blood	cells	
(RBCs).27,28		
Hemoglobin	is	found	in	RBCs,	and	it	is	the	protein	that	carries	oxygen	in	the	lungs	
to	all	other	body	tissues.	Healthy	RBCs	are	round,	flexible,	and	they	easily	pass	through	
small	blood	vessels	to	deliver	oxygen	to	organs	and	limbs.	Our	bone	marrow	makes	
RBCs,	which	typically	live	90	to	120	days	before	dying,	and	the	bone	marrow	replenishes	
those	RBCs	by	producing	a	new	supply.		
	 In	contrast,	“sickle”-shaped	RBCs	are	rigid,	so	it	is	more	difficult	for	sickled	RBCs	
to	pass	through	the	blood	vessels	compared	to	normal	RBCs.	As	a	result,	sickled	RBCs	
																																																						
26	Ledford,	H.	(2016).	CRISPR	deployed	to	combat	sickle-cell	anemia.	Nature.	
doi:10.1038/nature.2016.20782	
27	Dewitt,	M.	A.,	Magis,	W.,	Bray,	N.	L.,	Wang,	T.,	Berman,	J.	R.,	Urbinati,	F.,	...	Corn,	J.	E.	
(2016).	Selection-free	genome	editing	of	the	sickle	mutation	in	human	adult	
hematopoietic	stem/progenitor	cells.	Science	Translational	Medicine,	8(360).	
doi:10.1126/scitranslmed.aaf9336	
28	Sickle	Cell	Anemia.	(2014,	December	16).		
	
	 31	
can	block	blood	flow	in	the	blood	vessels	leading	to	the	organs	and	limbs,	preventing	
oxygen	from	reaching	the	body	tissues.	This	obstruction	of	blood	flow	can	consequently	
lead	to	organ	damage,	severe	pain,	and	also	increase	the	risk	for	infections.29,30	In	
addition	to	the	disorder’s	distinctive	“sickle”-shaped	RBCs,	the	abnormal	sickle	cells	
usually	only	live	for	about	10	to	20	days.	With	abnormal	sickle	cells’	much	shorter	life	
span,	the	body’s	bone	marrow	is	unable	to	produce	new	RBCs	at	the	speed	needed	to	
replace	the	dying	RBCs.	Consequently,	another	defining	characteristic	of	sickle-cell	
anemia	is	the	abnormally	low	number	of	RBCs	in	the	body	than	the	amount	that	is	
normally	needed	to	deliver	oxygen	efficiently	to	the	rest	of	the	body.		
	 Because	sickle-cell	anemia	is	an	inherited	blood	disorder,	a	child	can	have	sickle-
cell	anemia	if	either	of	the	two	situations	occurs:	both	of	the	child’s	parents	have	sickle-
cell	anemia,	meaning	each	parent	has	two	sickle-cell	genes,	or	if	both	of	the	parents	
have	the	sickle-cell	trait,	then	each	parent	has	only	one	sickle-cell	gene.	Inheriting	two	
sickle-cell	genes,	one	from	each	parent,	causes	the	child	to	have	sickle-cell	anemia.	After	
inheriting	this	disorder,	different	individuals	experience	varying	severities	of	the	disease;	
however,	sickle-cell	anemia	is	a	life-long	illness.		
Currently	some	of	the	treatments	to	alleviate	the	symptoms	of	sickle-cell	anemia	
include	blood	transfusions,	antibiotics,	and	pain	medications.	Those	with	sickle-cell	
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anemia	have	weakened	immune	systems	and	thus,	they	are	more	susceptible	to	
infections.	Taking	antibiotics	can	help	to	reduce	the	risk	of	getting	infections.	The	only	
potential	cure	is	a	bone	marrow	transplant,	but	this	route	raises	challenges:	it	is	not	
widely	available,	the	procedure	is	highly	risky,	and	locating	a	genetically-matched	donor	
is	difficult.31	Despite	recent	improvements	in	screening	and	treatment	options,	sickle-
cell	anemia	is	still	not	easily	treated	because	a	bone	marrow	transplant	is	highly	
dangerous	and	painful.	Scientists	are	hopeful	that	utilizing	a	gene-editing	solution	like	
CRISPR	will	allow	people	to	be	their	own	bone	marrow	donors	to	reduce	the	risks	
associated	with	transplants.32	
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The	Innovative	Genomics	Initiative	is	a	UC	Berkeley	and	UC	San	Francisco	joint	
effort	that	aims	to	use	CRISPR	to	correct	DNA	mutations	that	underlie	human	disease.33	
Contributing	to	that	effort,	in	a	sickle-cell	disease	study	published	in	October	2016	of	
the	online	journal	Science	Translational	Research,	researchers	from	UC	Berkeley,	UC	San	
Francisco	Benioff	Children’s	Hospital	Oakland	Research	Institute	(CHORI),	and	the	
University	of	Utah	School	of	Medicine	utilized	CRISPR	to	correct	the	single-gene	
mutation	responsible	for	sickle-cell	disease	in	hematopoietic	stem	cells	that	were	
isolated	from	the	blood	of	affected	patients.27,33	Hematopoietic	stem	cells	are	precursor	
cells	that	eventually	mature	into	RBCs.		
The	multi-institutional	team’s	main	goal	in	this	study	was	to	produce	healthy	new	
RBCs	using	gene-editing	methods	to	fix	the	mutation	in	patients’	own	stem	cells.	Of	the	
approximately	1	million	cells	that	were	injected	into	the	bone	marrow	of	seven	mice,	
12%	of	those	stem	cells	had	been	altered	with	CRISPR.	Four	months	later,	the	scientists	
found	an	average	of	2.3%	of	the	genetically-engineered	stem	cells	in	the	mice	retained	
the	edited	DNA	in	their	bone	marrow.	This	2.3%	level	of	correction	is	an	important	
advancement	because	the	researchers	believe	the	proportion	may	be	high	enough	to	
produce	a	substantial	clinical	benefit	in	sickle-cell	patients,	though	the	efficiency	of	the	
process	will	need	to	be	improved	for	practical	use.	Experts	believe	5%	-	10%	of	
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corrected	mutations	to	develop	healthy	RBCs	would	be	enough	to	cure	sickle	cell.34,35	In	
contrast,	the	rate	of	editing	the	sickle-cell	mutation	using	other	gene-editing	approaches	
was	less	than	one	percent.36	Since	the	CRISPR-edited	stem	cells	persisted	after	the	
transplant	into	the	mice,	there	could	be	a	potential	long-lasting	therapy	based	on	this	
approach.33		
Mark	DeWitt,	a	researcher	with	the	UC	Berkeley	Innovative	Genomics	Initiative,	
said	that	the	team’s	next	goal	with	the	mouse	study	is	to	increase	the	percentage	of	
altered	cells	that	are	present	in	the	bone	marrow	from	2%	to	5%	after	four	months.34	In	
addition,	the	study’s	researchers	emphasize	that	the	next	steps	for	future	pre-clinical	
work	will	involve	continued	optimization,	larger-scale	mouse	studies,	as	well	as	
meticulous	safety	analysis.	The	study	involved	injecting	mice	with	about	one	million	
CRISPR-edited	cells,	but	to	conduct	the	study	in	humans,	researchers	would	need	to	edit	
hundreds	of	millions	of	cells	by	scaling	up	the	ability	to	edit	genes.	There	are	also	safety	
concerns	with	utilizing	CRISPR	regarding	off-target	effects:	“some	of	the	inadvertent	
DNA	changes	could	cause	other	serious	diseases”.35	For	example,	using	CRISPR	to	treat	
sickle	cell	disease	could	instead	lead	to	a	mutation	in	the	gene	that	causes	another	
serious	condition	called	beta	thalassemia,	a	blood	disorder	that	reduces	hemoglobin	
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production.	Consequently,	the	researchers	aim	to	expand	their	study	to	include	more	
lab	animals	to	demonstrate	that	CRISPR-editing	blood-forming	cells	is	reasonably	safe.		
Biotechnology	companies	are	becoming	actively	interested	in	using	CRISPR	to	
develop	new	treatments	for	sickle-cell	disease.	Biotechnology	companies	are	major	
players	in	the	commercialization	of	gene-editing	technology.	In	October	2015	two	
biotechnology	companies,	Vertex	Pharmaceuticals	and	CRISPR	Therapeutics,	entered	
into	a	four-year	strategic	research	collaboration	to	use	the	CRISPR	technology	to	
discover	and	develop	potential	new	treatments	targeting	the	genetic	causes	of	human	
disease.	One	of	the	two	companies’	initial	focuses	is	to	discover	treatments	to	address	
the	known	genes	and	mutations	that	contribute	to	and	cause	sickle-cell	disease.37		
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Antisense	Technology	in	Flavr	Savr	Tomato	Case	Study	
	
	 In	the	1990s,	the	Flavr	Savr	tomato	became	the	first	commercialized	genetically	
engineered	food	product.	This	crop	product’s	journey	from	the	lab	to	the	market	
exemplifies	the	challenges	faced	at	the	intersection	of	science,	business,	and	social	
perceptions.	First	Fruit:	The	Creation	of	the	Flavr	Savr	Tomato	and	the	Birth	of	
Genetically	Engineered	Food,	written	by	Belinda	Martineau,	one	of	the	researchers	who	
developed	the	Flavr	Savr	tomato,	details	the	tomato’s	journey	from	successfully	being	
the	first	commercially	sold,	genetically	engineered	whole	food	through	the	time	of	its	
eventual	demise.	With	the	aid	of	Martineau’s	book,	I	outline	and	discuss	the	main	
events	of	the	Flavr	Savr	tomato	case	study	in	order	to	establish	a	foundation	for	
comparison	to	the	sickle-cell	anemia	CRISPR	case	study	explored	in	the	previous	
chapter.		
In	early	1988,	Calgene,	Inc.,	an	independent	agricultural	biotechnology	company	
in	Davis,	California,	was	growing	tomato	plants	that	contained	the	antisense	
polygalacturonase	(PG)	gene.	However,	at	the	time,	Calgene	did	not	plan	to	establish	
the	tomato	as	a	potential	commercial	opportunity.	Instead,	the	focus	was	on	developing	
the	company’s	herbicide-resistance	program	and	the	BromoTol	gene,	which	could	help	
crop	plants	resist	an	herbicide	that	would	typically	kill	them.	Within	a	few	months,	
though,	a	significant	discovery	from	a	scientific	experiment	involving	the	tomatoes	
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growing	at	Calgene	marked	a	turnaround	in	the	company’s	interests	in	the	agricultural	
biotechnology	industry.	
In	the	scientific	experiment,	Calgene	scientists	had	two	different	groups	of	
tomato	plants:	one	group	had	the	genetically	inserted	Flavr	Savr	tomato	gene	that	
utilized	“antisense	technology”	and	the	other	group	was	nonengineered.	Tomatoes	
were	harvested	from	the	genetically	engineered	tomato	plants	and	from	the	
nonengineered	tomato	plants	–	these	harvested	tomatoes	were	kept	at	room	
temperature	and	observed	over	time.	In	three	to	four	weeks,	the	tomatoes	with	the	
antisense	PG	gene	still	looked	and	felt	as	if	they	were	freshly	picked,	whereas	the	non	
GMO	tomatoes	were	shriveled	and	rotting.	The	stark	difference	between	these	two	
groups	demonstrated	that	the	tomatoes	with	the	antisense	PG	gene	had	a	dramatically	
longer	shelf	life	than	that	of	ordinary	tomatoes.	This	promising	observation	began	to	
garner	the	attention	of	Calgene’s	management	to	use	the	antisense	PG	gene	as	a	
potential	business	prospect	in	tomatoes.	
A	persistent	issue	the	tomato	industry	had	been	facing	was	trying	to	provide	
fresh-market	tomatoes	to	consumers.	For	the	fresh	market	tomato	industry,	it	was	
essential	for	tomatoes	to	survive	shipment	to	markets.	Calgene	aimed	to	change	the	
fresh	tomato	business	with	the	observations	from	its	experiment:	the	company	wanted	
to	position	the	Flavr	Savr	tomatoes	as	the	epitome	of	vine-ripened,	high-quality	
tomatoes.		
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The	issue	fresh-tomato	businesses	faced	was	that	when	non-GMO	tomatoes	
reached	grocery	stores	they	would	soften	and	rot	on	the	shelf	before	they	could	be	sold.	
Plant	breeders	worked	for	decades	to	toughen	and	improve	tomatoes’	shippability.	
Traditionally,	one	solution	to	address	this	problem	was	to	pick	the	tomatoes	when	they	
were	still	unripe,	firm	to	the	touch	and	completely	green.	When	these	tomatoes	were	
hard	and	green,	they	could	survive	the	transport	to	distributors	and	grocery	stores,	
where	ethylene	gas	was	used	to	artificially	ripen	the	tomatoes.	However,	even	though	
the	“gassed”	tomatoes	looked	red	and	ripe,	they	did	not	attain	the	full	flavor	that	vine-
ripened	tomatoes	possessed.	American	consumers	expressed	dissatisfaction	with	the	
taste	of	artificially-ripened	tomatoes.	Although	American	consumers	complained	about	
the	taste	of	fresh	tomatoes,	each	American	consumer	purchased	an	average	of	17	
pounds	of	fresh	tomatoes	every	year.		
	From	the	Calgene	tomato	experiment,	scientists	concluded	that	a	second	and	
potentially	more	effective	solution	than	gassing	green	tomatoes	involved	eliminating	
the	PG	protein	in	the	tomato	fruit	by	expressing	an	antisense	PG	gene	to	construct	the	
Flavr	Savr	tomato.	Scientists	could	then	extend	ripe	tomatoes’	shelf	life	so	that	
customers	would	buy	the	tomatoes	before	they	displayed	signs	of	rotting	or	damage,	
and	the	antisense	PG	gene	might	even	help	improve	the	taste	of	the	tomatoes.	With	the	
$4	billion	fresh	tomato	market,	introducing	Flavr	Savr	tomatoes	seemed	to	be	a	
compelling	solution	to	the	fresh	market	tomatoes	problem.	Not	only	would	consumers	
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buy	more	tomatoes,	but	also	the	company	predicted	consumers	would	be	willing	to	pay	
more	in	exchange	for	enjoying	more	flavorful	tomatoes.		
To	more	clearly	understand	antisense	technology’s	role	in	gene	editing,	it	is	
important	to	understand	the	basic	mechanism	of	how	proteins	are	formed	in	two	steps:	
transcription	and	then	translation.	In	the	first	step,	the	genetic	code	of	a	gene	is	
transcribed	into	mRNA,	and	then	the	mRNA	travels	to	the	ribosomes,	where	the	second	
step	occurs.	In	the	second	step,	the	mRNA	serves	as	a	set	of	instructions	for	the	
ribosomes	to	translate	the	mRNA’s	genetic	code	into	amino	acids,	which	are	the	
building	blocks	of	proteins.	See	Figure	2.		
	
Figure	2	from	Antisense	DNA	Oligonucleotide	by	Robinson	R	[CC	BY	2.5	
(http://creativecommons.org/licenses/by/2.5)],	via	Wikimedia	Commons	
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Antisense	technology	is	able	to	silence	a	gene’s	effect	by	inhibiting	the	
translation	step.	This	tool	aims	to	silence,	or	turn	off,	a	gene’s	effect,	instead	of	
correcting	a	mutated	gene.38	The	term	“antisense”	describes	the	sequence	that	is	
complementary	to	the	DNA	or	RNA	sequence	while	“sense”	refers	to	the	original	DNA	or	
RNA	sequence.	The	general	principle	behind	antisense	technology	involves	base	pairing	
an	antisense	nucleic	acid	sequence	with	its	complementary	sense	RNA	sequence	–	the	
cell	will	not	recognize	the	double	helix,	and	so,	the	cell	will	proceed	to	degrade	the	
faulty	RNA	sequence.	With	a	degraded	RNA,	the	cell	does	not	have	a	sequence	to	
translate,	and	consequently,	the	cell	is	not	able	to	build	the	protein.		
Researchers	capitalized	on	this	naturally	occurring	process	to	develop	antisense	
technology	as	a	gene-editing	tool	to	provide	the	instructions	to	inhibit	gene	expression	
and	prevent	protein	formation	in	tomatoes.	The	antisense	PG	gene	that	the	researchers	
co-opted	for	use	in	tomatoes	comprised	of	a	copy	of	a	tomato	fruit	gene	that	coded	for	
polygalacturonase	(PG),	an	enzyme	that	is	involved	in	fruit	ripening.	The	PG	gene	in	non	
GMO	tomatoes	and	the	engineered	antisense	PG	gene	differed	in	one	primary	way:	the	
engineered	gene	was	flipped	upside	down	and	backward,	resulting	in	the	antisense	PG	
gene.	This	antisense	PG	gene	was	capable	of	shutting	down	the	natural	process	of	PG	
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protein	production	in	the	tomatoes,	thereby	slowing	down	the	process	of	fruit	ripening.	
See	Figure	3.		
	
	
Figure	3	adapted	from	Antisense	DNA	Oligonucleotide	by	Robinson	R	[CC	BY	2.5	
(http://creativecommons.org/licenses/by/2.5)],	via	Wikimedia	Commons	
	
	
	
	
	
Flavr	Savr	Tomato	
Antisense	PG	Gene		
	 42	
Calgene	scientists	understood	the	process	by	which	the	antisense	PG	gene	shut	
down	PG	production	in	the	genetically-engineered	tomatoes.	However,	many	of	the	
scientists,	including	William	(Bill)	Hiatt	who	was	the	head	scientist	in	charge	of	Calgene	
tomato	research	was	hesitant	to	publish	the	preliminary	observations	based	on	this	one	
experiment.	When	the	media	heard	about	the	Calgene	experiment’s	results,	news	
reporters	eagerly	wanted	to	cover	the	story	about	the	potential	for	longer-lived	
tomatoes.	Calgene	scientists,	though,	deferred	from	talking	to	the	press,	because	they	
were	not	confident	about	the	validity	of	the	experiment’s	results.	After	additional	
testing,	scientists	found	that	Flavr	Savr	tomatoes	ripened	normally,	but	that	PG	activity	
had	a	more	dominant	role	in	the	deterioration	of	the	tomato	during	the	overripe	stage	
of	ripening.	What	was	the	advantage	for	a	fresh-market	tomato	business	if	these	
genetically-modified	tomatoes	still	underwent	the	initial	process	of	fruit	softening	
normally?	On	the	other	hand,	those	who	were	part	of	Calgene’s	business	planning	effort	
decided	to	make	an	extrapolation	of	the	Flavr	Savr	tomato	shelf-life	phenomenon,	
inventing	this	product	and	outlining	the	company’s	positioning	for	commercializing	vine-
ripened,	high-quality	tomatoes.		
Calgene	believed	that	consumers’	appeal	for	tasty,	vine-ripe	tomatoes	was	
enough	to	offset	consumers’	wariness	of	the	antisense	technology	used	in	Flavr	Savr	
tomatoes.	The	company	hoped	that	since	the	technology	introduced	a	genetically	
modified	piece	of	DNA	that	contained	an	antisense	gene	from	the	same	organism,	it	
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would	help	ease	consumer	acceptance	of	the	Flavr	Savr	tomato,	as	well	as	help	increase	
the	chance	of	successfully	attaining	approval	for	commercializing	the	product	from	U.S.	
regulatory	agencies.		
	
Legal	Challenges	–	Patent	Interference	
	
	 In	1992,	the	U.S.	Patent	Office	issued	a	patent	to	Calgene	for	the	use	of	antisense	
technology	to	shut	off	any	gene	in	any	plant	cell.	Though	it	appeared	that	Calgene’s	use	
of	this	technology	was	protected,	Calgene	was	not	the	only	one	who	was	issued	
antisense	patents.	The	State	University	of	New	York	was	issued	three	broad	antisense	
patents,	and	then	it	exclusively	licensed	those	patents	to	Enzo	Biochem,	Inc.	What	
ensued	were	suits	and	countersuits	from	both	Calgene	and	Enzo	alleging	patent	
infringement,	patent	invalidity,	and	unfair	competition.	In	one	suit,	Enzo	alleged	that	
Calgene	committed	willful	patent	infringement.	All	of	Calgene’s	employees,	about	150	
at	the	time,	had	to	turn	in	documents	and	notebooks	that	had	any	mention	of	the	use	of	
antisense	technology	–	this	perusal	found	that	of	the	over	2,300	lab	notebooks	half	of	
them	contained	work	related	to	antisense	technology.	In	1993,	it	was	already	widely	
known	that	Calgene	was	utilizing	antisense	technology;	Calgene	scientists	felt	that	the	
time	and	effort	invested	in	investigating	all	the	documents	and	notebooks	was	a	waste	
of	time.	Instead,	scientists	believed	the	focus	should	have	been	on	establishing	the	
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validity	of	Calgene’s	antisense	patents	rather	than	addressing	Enzo’s	infringement	
claims.		
	 In	1995,	the	Enzo	patent	case	went	to	trial.	The	trial	centered	on	four	main	
patent	issues:	enablement,	inequitable	conduct,	obviousness,	and	prior	art.	In	the	first	
issue	of	enablement,	although	Masayori	Inouye	at	the	State	University	of	New	York,	
who	was	issued	the	three	broad	antisense	patents	and	later	licensed	them	to	Enzo	
Biochem,	Inc.,	did	perform	the	antisense	work	before	Calgene,	Calgene	claimed	that	
Inouye	did	not	“sufficiently	[enable]	someone	skilled	in	the	art	to	use	the	invention	in	
plants”	(209).	Inouye	antisensed	three	different	genes;	however,	they	were	in	E.	coli,	the	
bacteria.	Calgene	argued	that	his	work	with	antisense	technology	in	a	bacterial	cell	did	
not	demonstrate	that	the	technology	could	work	in	a	plant	cell.	The	second	issue	of	
inequitable	conduct	surfaced	when	Inouye	neglected	to	disclose	to	the	USPTO	about	the	
other	cellular	systems	he	had	taken	that	did	not	succeed.	The	third	issue	of	obviousness	
involved	Enzo’s	claim	that	after	Inouye’s	antisense	results	in	E.	coli,	utilizing	antisense	in	
plants	was	a	logical	next	step.	Therefore,	Enzo	argued	that	the	USPTO	should	not	have	
issued	the	antisense	patent	to	Calgene	from	the	start.		
The	fourth	and	last	patent	issue	of	the	trial	involved	prior	art.	Calgene	previously	
cited	published	research	conducted	at	Harold	Weintraub’s	lab	at	the	Fred	Hutchinson	
Cancer	Research	Center	in	Seattle	in	its	original	patent	application,	so	the	question	was	
whether	Inouye’s	antisense	work	came	before	the	research	conducted	at	the	cancer	
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research	center	on	a	calendar	basis.	Calgene	obtained	a	nonexclusive	license	to	
Weintraub’s	own	antisense	patent	application.	If	Weintraub’s	work	was	first,	then	based	
on	prior	art	Inouye’s	work	may	be	seen	as	obvious.	However,	the	biggest	controversy	in	
the	entire	case	that	related	to	the	prior	art	issue	was	that	Enzo	claimed	that	
Weintraub’s	lab	engaged	in	scientific	misconduct	when	preparing	to	publish	the	
antisense	work.	To	investigate	this	allegation,	Enzo	brought	in	Walter	Gilbert,	the	Nobel	
laureate	from	Harvard.	He		concluded	that	there	was	manipulation	of	the	data	to	make	
it	appear	extremely	accurate.	To	counter	these	claims,	the	Fred	Hutchinson	Cancer	
Research	Center	responded	by	conducting	an	internal	investigation	and	found	that	
Gilbert’s	allegation	was	without	merit.		
From	Calgene’s	perspective,	the	Wall	Street	Journal	increased	the	company’s	
troubles	when	the	Journal	published	an	article	that	had	incorrect	information,	stating	
that	Calgene	was	attempting	to	attain	a	patent	for	the	antisense	technology,	when	in	
fact,	Calgene	had	already	been	issued	its	antisense	patent	three	years	ago.	Additionally,	
the	article	stated	that	“[Calgene]	losing	the	case	might	delay	[its]	nationwide	rollout	of	
the	Flavr	Savr…and	jeopardize	its	stated	plans	to	become	profitable	in	1996”	(211),	
causing	Calgene	to	question	the	Journal’s	intentions.	Calgene’s	CEO	Roger	Salquist	
responded	to	the	article	and	said	that	the	outcome	of	the	patent	trial	would	not	impact	
the	rollout	of	Calgene’s	Flavr	Savr	tomatoes;	fortunately,	the	Journal	immediately	
printed	a	corrected	version	of	the	article	the	following	day.	In	1996,	the	Enzo	patent	
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decision	came	out	–	U.S.	District	Court	Judge	Joseph	J.	Farnan	ruled	Enzo’s	antisense	
patents	invalid	and	upheld	Calgene’s	antisense	patent,	so	there	was	no	need	to	address	
whether	Calgene	had	infringed	on	Enzo’s	patents.	Later	in	1999,	the	federal	appeals	
courts	decided	to	only	rule	parts	of	two	of	Enzo’s	three	antisense	patents	were	invalid,	
limiting	the	district	court’s	judgment	in	1996	of	the	invalidity	of	Enzo’s	antisense	
patents.		
	
Clash	Between	the	Science	and	Business	Cultures	at	Calgene	
The	inception	of	this	new	fresh	tomato	project	naturally	brought	the	business	
and	science	sides	of	Calgene	together,	introducing	conflicts	of	interest.	A	kind	of	
“culture	shock”	was	injected	into	the	company.	Calgene’s	business	executives	were	
excited	about	the	potential	business	opportunity	of	developing	and	commercializing	
tomatoes	that	could	be	ripened	while	still	on	the	vine	and	yet	still	maintain	the	firmness	
necessary	to	endure	the	shipment	process.	The	business	staff	believed	that	further	
testing	was	the	only	obstacle	standing	between	the	perception	and	the	reality	of	tastier,	
higher-quality	fresh	tomatoes.	Calgene	scientists,	however,	were	less	optimistic	about	
the	Flavr	Savr	tomato	–	there	was	experimental	evidence	supporting	the	possibility	of	a	
tomato	with	a	longer	shelf	life,	but	scientists	did	not	have	data	supporting	the	claim	that	
a	vine-ripened	tomato	could	endure	the	journey	to	grocery	stores.	Without	empirically-
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derived	evidence	supporting	the	hypothesis,	the	scientists	feared	that	the	fresh	tomato	
Calgene	business	executives	hoped	to	develop	would	not	become	a	reality.	
	 With	the	introduction	of	the	Flavr	Savr	tomato	project,	Calgene’s	business	impact	
on	its	science	was	apparent	when	layoffs	among	the	science	staff	occurred	in	1988,	only	
the	second	occurrence	of	layoffs	in	the	company’s	history.	Business	executives	
explained	that	high	R&D	spending	caused	the	financial	losses	in	1988	that	resulted	in	
the	layoffs.	However,	the	report	to	shareholders	indicated	that	Calgene’s	management	
team	had	failed	to	reach	its	financial	targets,	yet	the	science	staff	had	to	pay	for	it.	How	
Calgene	would	approach	its	business	strategy	with	the	new	Flavr	Savr	tomato	project	
was	another	source	of	disagreement	between	Calgene’s	business	executives	and	
scientists.	
	 Calgene’s	management	team	wanted	to	invest	in	a	vertical	integration	strategy,	
building	up	several	different	businesses	in	order	to	generate	the	kind	of	money	that	only	
vertical	integration	could	supply.	But	rather	than	investing	in	multiple	businesses	or	
products,	some	Calgene	scientists	were	more	supportive	of	a	“gene	boutique”	where	
they	believed	Calgene	should	continue	doing	what	it	did	best:	cloning	genes,	
transferring	the	genes	to	and	expressing	them	in	plants,	and	ultimately	selling	or	
licensing	those	cloned	genes	to	agricultural	businesses.	Calgene	scientists	understood	
that	in	order	for	Calgene	to	survive,	the	company	needed	to	make	money;	however,	
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there	were	still	conflicts	of	interest	between	management	and	the	science	staff	that	led	
to	many	of	the	challenges	contributing	to	Calgene’s	demise.		
	 One	of	the	first	impacts	to	Calgene’s	transition	to	business	mode	involved	the	
creation	of	Calgene	Fresh,	Inc.,	a	subsidiary	of	Calgene	that	served	as	the	company’s	
marketing	arm	but	had	a	separate	management	team	and	kept	its	own	books	for	
business	purposes.	Establishing	Calgene	Fresh	meant	that	Calgene	would	be	undergoing	
a	reorganization:	Calgene	tomato	scientists	would	be	consolidated	into	one	lab.	Prior	to	
the	introduction	of	the	Flavr	Savr	tomato	idea,	Calgene	scientists	were	largely	left	to	
their	own	devices	and	found	throughout	the	company’s	labs.	The	scientists	enjoyed	
scientific	independence	as	well	as	the	opportunity	to	integrate	and	collaborate	with	
other	scientists	who	were	working	on	different	projects:	there	was	the	sharing	of	ideas,	
materials,	successes,	and	failures.	Calgene’s	management	believed	that	bookkeeping	
would	be	simpler	if	the	scientists	working	on	the	Flavr	Savr	tomatoes	were	segregated	
from	the	other	Calgene	scientists.	In	contrast,	the	scientists	thought	that	easier	
bookkeeping	was	not	an	adequate	reason	to	segregate	the	tomato	scientists	from	
everyone	else.	Rather,	the	scientists	knew	that	it	would	take	some	time	to	adjust	to	the	
new	lab	environment	at	Calgene	Fresh,	and	during	that	time	their	research	efficiency	
would	significantly	be	reduced.	Additionally,	the	reorganization	and	segregation	of	the	
scientists	introduced	the	possibility	for	internal	strife	among	the	scientists:	there	were	
questions	about	whether	the	tomato	group	would	receive	preferential	treatment,	
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better	lab	space,	inter	alia?	These	questions	began	to	erode	the	strong	scientific	
community	at	Calgene.		
	 Once	Calgene	Fresh	was	created,	Salquist	believed	that	Thomas	Churchwell,	who	
was	a	member	of	Calgene’s	board	of	directors	and	had	sales	expertise,	would	be	a	great	
choice	as	the	president	and	CEO	of	this	subsidiary.	However,	it	was	clear	to	the	
scientists	that	Churchwell	was	not	fit	to	lead	Calgene	Fresh	and	market	the	Flavr	Savr	
tomato	to	success.	Scientists	believed	he	made	decisions	that	did	not	make	sense	–	for	
example,	he	chose	to	move	Calgene	Fresh’s	central	offices	to	Evanston,	Illinois,	as	far	
away	as	possible	from	major	fresh	tomato	growing	centers	in	California	and	Florida.	
There	were	three	key	issues	between	the	business	and	science	staff	that	contributed	to	
Calgene’s	demise:	the	lack	of	communication,	the	culture	clash	between	management	
and	scientists,	and	the	lack	of	business	expertise.		
	 The	first	issue	was	the	lack	of	clear	communication	between	management	and	
scientists.	Churchwell	expounded	his	plan	to	develop	a	new	corporate	culture	at	
Calgene	Fresh,	one	that	upheld	open	communication	among	all	employees.	Although	
the	scientists	respected	Churchwell’s	sincerity	in	his	visions	for	Calgene	Fresh,	the	
scientists	felt	that	Calgene’s	corporate	culture	already	reflected	the	open	
communication	and	collaboration	that	he	was	envisioning.	However,	from	the	scientists’	
interactions	with	Churchwell,	his	use	of	circumlocution	in	his	manner	of	communication	
caused	the	scientists	to	believe	that	that	way	of	speaking	was	common	in	business.	
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Churchwell’s	confusing,	indirect	communication	elicited	doubts	among	the	scientists	
that	he	would	be	able	to	facilitate	effective	communication	at	Calgene	Fresh.	
	 The	second	issue	involved	the	clash	of	business	and	science	cultures.	As	part	of	
developing	a	new	corporate	culture,	Churchwell	created	organizational	vision	meetings	
that	focused	on	establishing	Calgene	Fresh’s	core	values	and	beliefs,	defining	quality,	
and	most	importantly	on	integrating	the	scientists	into	the	business	and	creating	a	
common	culture	and	language.	Still,	the	scientists	at	Calgene	Fresh	preferred	to	discuss	
scientific	plans	and	their	results	rather	than	the	organizational	decisions	around	them.			
	 The	business	and	science	staff	not	understanding	one	another’s	values	and	
practices	created	another	source	of	contention	between	the	two.	The	business	staff	
wanted	concrete	numbers	and	definite	answers	from	experiments;	however,	the	
scientists	explained	that	there	were	chances	where	scientific	experiments	may	not	
demonstrate	identifiable	correlations.	Scientists	were	surprised	that	even	after	several	
years	working	at	Calgene	the	business	staff	still	did	not	understand	the	basic	definition	
of	an	experiment.		
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Lack	of	Sufficient	Business	Expertise	
	
	 Calgene	Fresh	did	not	understand	agriculture,	what	tomato	varieties	to	grow,	nor	
how	to	handle	the	fruit	–	there	was	an	evident	lack	of	sufficient	business	knowledge	in	
managing	the	tomato	business.	There	were	two	anecdotes	that	clearly	portray	the	
consequences	of	this	issue.		
When	Churchwell	was	appointed	to	head	Calgene	fresh,	the	Calgene	board	of	
directors	told	him,	“The	good	news	is	that	you	know	nothing	about	the	tomato	business	
so	you	won’t	fall	into	the	old	traps	that	[others]	have.	The	bad	news	is	that	you	know	
nothing	about	the	tomato	business	and	you’ll	fall	into	traps	that	they	know	how	to	
avoid”	(136).	With	this	insight,	Churchwell	knew	he	had	to	establish	partnerships	who	
were	committed	to	fresh	quality	and	could	supply	Calgene	Fresh	with	a	large	amount	of	
tomatoes.	Calgene	Fresh	was	on	a	steep	tomato	market	learning	curve.		
	 In	one	anecdote,	Calgene’s	marketing	strategy	in	promoting	the	Flavr	Savr	
tomatoes	in	grocery	stores	was	unsuccessful.	Not	long	after	Calgene	started	selling	the	
Flavr	Savr	tomatoes,	the	number	of	damaged,	unusable	tomatoes,	or	shrink,	was	as	high	
as	50%	of	the	available	tomatoes	and	had	to	be	thrown	away.	To	address	this	issue,	
Calgene	Fresh	created	a	sales	incentive	program	where	it	agreed	to	repurchase	fruits	a	
grocery	store	did	not	sell,	in	order	to	attain	retail	space	for	Flavr	Savr	tomatoes.	
However,	this	strategy	only	continued	to	increase	shrink	levels,	making	it	much	more	
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expensive	and	challenging	to	provide	consistently	flavorful	and	superior	texture	Flavr	
Savr	tomatoes	to	consumers.		
	 The	second	anecdote	portrays	Calgene’s	lack	of	knowledge	about	the	best	places	
to	grow	tomatoes	and	tomato	handling	techniques.	To	help	increase	the	quality	of	the	
tomatoes,	and	consequently	decrease	the	shrink	levels	and	costs	Calgene	strategically	
turned	to	the	help	of	experienced	tomato	grower-shipper	partnerships.	Calgene	Fresh	
successfully	executed	deals	with	three	tomato	suppliers	and	had	a	growing	location	in	
Mexico,	which	could	help	produce	a	year-round	supply	of	tomatoes.	However,	Mexico	
tomato	shipping	tests	were	disappointing.	Flavr	Savr	tomatoes	that	traveled	by	truck	
from	Mexico	to	Chicago	would	be	damaged	along	the	journey,	causing	high	expenses	
due	to	the	loss	of	tomato	supply.	This	was	only	the	beginning	of	Calgene	Fresh’s	honing	
of	tomato	shoveling	over	the	next	few	years.		
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	 Comparative	Case	Analysis	 	
CRISPR	in	Sickle-Cell	Anemia	and	Antisense	in	Flavr	Savr	Tomatoes	
	
	 Genome-editing	technology,	such	as	CRISPR	and	antisense	technology,	are	just	
two	of	the	genetic	tools	researchers	utilize	to	study	genomes	and	to	investigate	the	
effects	of	altering	genes.	The	application	of	antisense	technology	in	Flavr	Savr	tomatoes	
occurred	in	the	late	1980s	while	CRISPR’s	application	in	sickle-cell	anemia	is	currently	in	
progress.	In	this	section,	I	will	conduct	a	comparative	analysis	of	these	two	case	studies,	
using	the	lessons	learned	from	the	Flavr	Savr	tomatoes	case	as	a	“lens”	through	which	
to	view	the	use	of	CRISPR	in	the	sickle-cell	anemia	case.	I	will	consider	the	use	of	CRISPR	
and	its	path	to	commercialization	in	three	areas:	legal	implications,	ethical	implications,	
and	the	convergence	of	science	and	business.	By	considering	the	impact	of	CRISPR	
technology	in	these	three	areas,	guidelines	and	recommendations	can	be	implemented	
to	support	future	applications	and	commercialization	of	CRISPR.	
	
Legal	Implications	
	
	 The	antisense	technology	patent	dispute	between	Calgene	and	Enzo	was	less	
contentious	compared	to	the	CRISPR	patent	dispute	between	Jennifer	Doudna’s	and	
Feng	Zhang’s	teams.	Before	Calgene	adopted	antisense	technology	to	create	the	Flavr	
Savr	tomato,	companies	did	not	have	experience	using	antisense	technology	to	maintain	
a	tomato’s	ripeness	from	the	vine	to	the	store	while	also	guaranteeing	a	flavorful	taste.	
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All	the	potential	applications	of	this	technology	were	still	being	explored	in	the	1980s,	so	
the	most	well-known	application	of	antisense	technology	was	in	the	Flavr	Savr	tomato.		
	 Genome-editing	technologies	have	been	evolving	to	embrace	more	
sophisticated,	advanced	characteristics.	For	example,	both	zinc-finger	nucleases	(ZFNs)	
and	transcription	activator-like	effector	nucleases	(TALENs)	both	use	a	non-specific	
nuclease	to	cut	the	target	sequence,	but	CRISPR	demonstrates	a	simpler,	more	precise	
target	mechanism.	CRISPR	does	not	rely	on	DNA	recognition	of	the	target	sequence	to	
edit	the	genome,	so	guide	RNAs	can	be	easily	and	cheaply	designed	to	target	almost	any	
sequence	in	the	genome	specifically.39		
Since	CRISPR’s	discovery	and	the	beginning	of	the	CRISPR	patent	dispute	in	2012,	
the	optimism	about	the	technology’s	scientific	potential	has	grown	considerably	in	just	a	
few	years.	With	the	numerous	applications	CRISPR	can	offer	that	suggest	more	effective	
solutions	to	our	current	issues	with	genome	editing,	such	as	the	challenge	of	achieving	
more	precise	and	accurate	modifications	of	our	genome,	Doudna’s	and	Zhang’s	teams	
are	willing	to	incur	the	expenses	and	time	to	battle	for	the	rights	to	use	CRISPR.	There	is	
additional	incentive	to	undergo	this	CRISPR	patent	dispute,	because	the	team	that	is	
granted	those	rights	will	reap	the	profit	that	comes	from	licensing	this	technology	to	
other	companies.		
																																																						
39	Yeadon,	P.	J.	(2014,	March	4).	Pros	and	cons	of	ZNFs,	TALENs,	and	CRISPR/Cas.		
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Ethical	Implications	
	
	 In	the	1970s,	Hebert	Boyer	founded	Genentech,	the	first	biotechnology	company.	
Since	then,	the	biotechnology	industry	has	undergone	significant	advances.	The	1980s	
brought	the	first	biotech	drugs	available	on	the	market.	In	the	1990s,	the	first	
genetically-engineered	food	product,	the	Flavr	Savr	tomatoes,	were	commercialized.	
Today,	genome-editing	technology	is	setting	the	stage	for	new	biotechnology	products,	
but	this	new	technology	also	introduces	risk	and	ethical	dilemmas.			
Society’s	struggle	with	addressing	the	ethical	use	of	genome-editing	technologies	
is	not	new.	In	response	to	Boyer	and	Cohen’s	development	of	recombinant	DNA	
technology	in	the	1970s,	in	public	hearings	hosted	in	local	communities,	people	
articulated	their	safety	and	misuse	concerns	about	this	new,	unfamiliar	technology.40	At	
that	time,	scientists	were	confident	that	recombinant	DNA	technology	would	offer	
significant	opportunities;	however,	the	potential	risks	of	using	it	in	the	lab	were	unclear.	
In	February	1975,	scientists	organized	the	Asilomar	Conference	to	set	standards	for	
conducting	research	with	recombinant	DNA	technology	without	endangering	public	
safety	and	health.	Ethical	implications	of	this	technology	were	not	discussed	at	the	
conference,	however.	Scientists	had	not	considered	the	implications	beyond	the	lab	at	
this	time,	because	they	did	not	see	the	importance	of	addressing	those	downstream	
implications.	This	conference	marked	the	start	of	public	discussion	on	scientific	policy	
																																																						
40	Rosenblatt,	D.	P.	(1982,	August	1).	The	Regulation	of	Recombinant	DNA	Research:	The	
Alternative	of	Local	Control.		
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involving	genomic-engineering.	Since	then,	a	myriad	of	new	genome-editing	issues	have	
surfaced,	such	as	stem	cell	research	and	cloning,	suggesting	that	public	concerns	about	
the	ethical	implications	of	genome-editing	technologies	have	become	more	complex	
and	pose	greater	risks	in	the	transition	of	these	technologies	from	the	lab	to	the	
market.41	Addressing	the	potential	ethical	implications	of	utilizing	genome-editing	
technologies	is	one	of	the	critical	steps	towards	responsible	development	and	
application	of	the	technologies.		
Throughout	the	Flavr	Savr	tomato’s	short-lived	commercial	run,	consumers’	
demand	for	the	tomatoes	surpassed	its	supply.	During	this	time,	public	concern	over	the	
“antisensed”	tomatoes	was	not	an	issue.	Calgene’s	transparency	about	tomato	
experiment	results	and	the	use	of	antisense	technology	in	the	crop	inspired	consumers’	
good	will.42	
Antisense	technology	in	the	Flavr	Savr	tomato	case	study	did	not	include	DNA	
from	another	organism	–	the	antisense	PG	gene	came	from	manipulating	the	PG	gene	in	
a	tomato,	similar	to	how	a	human’s	own	cells	were	edited	with	CRISPR	to	correct	for	
sickle	cell.	In	both	cases,	DNA	from	another	organism	was	not	introduced.	The	genetic	
																																																						
41	Finegold,	D.	L.,	Bensimon,	C.	M.,	&	Daar,	A.	S.	(2005).	Bioindustry	Ethics.	Amsterdam:	
Elsevier.	
42	Test	Tube	Tomato	[Video	file].	(2013,	June	24).		
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modification	was	minimal	in	the	tomatoes,	another	reason	why	there	were	fewer	
ethical	concerns	about	the	use	of	this	technology	to	develop	Flavr	Savr	tomatoes.	
Currently,	there	are	two	main	ethical	concerns	about	human	genome-editing.	
One	concern	involves	making	heritable,	permanent	changes	to	the	germ	line,	or	the	
sperm	and	egg	cells.	A	second	concern	involves	the	safety	of	the	technology,	ensuring	
that	off-target	effects	are	minimal.	Using	CRISPR	to	fix	sickle-cell	anemia	involves	editing	
a	patient’s	own	cells	outside	of	the	body.	This	process	of	editing	avoids	off-target	
effects,	since	these	edited	stem	cells	will	populate	in	the	bone	marrow	to	make	other	
blood	cells.	Researchers	involved	with	the	UC	Berkeley	Innovative	Genomics	Initiative	
are	attempting	to	improve	the	safety	of	utilizing	CRISPR	by	conducting	experiments	with	
greater	numbers	of	lab	animals.	With	a	greater	study	sample,	researchers	can	more	
easily	identify	what	lab	methods	and	modifications	to	the	CRISPR	system	will	contribute	
to	the	safe	use	of	CRISPR.	The	focus	to	improve	safety	in	using	CRISPR	to	correct	for	
sickle-cell	anemia	involves	reducing	the	likelihood	of	off-target	effects	that	could	lead	to	
other	serious	diseases,	such	as	beta	thalassemia,	another	type	of	genetic	blood	
disorder.			
	 In	both	antisense	technology	and	CRISPR,	off-target	effects	are	still	a	significant	
concern.	It	is	unrealistic	to	presume	that	a	tool	can	be	100%	accurate	and	precise,	but	
we	can	strive	to	get	close	to	that	level	of	accuracy	and	precision.	The	multitude	of	
potential	applications	for	CRISPR	is	unique	to	this	technology,	especially	since	it	has	the	
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ability	to	make	applications	like	enhancement	and	personalized	medicine	that	were	
once	just	fantasies	become	realities,	but	the	off-target	effects	can	serve	as	a	hindrance	
to	these	developments.	This	safety	concern	explains	why	scientists	are	working	to	
continue	improving	the	structure	and	mechanisms	of	the	CRISPR	technology.	More	
complex	than	the	ethical	concerns	in	the	Flavr	Savr	tomatoes,	the	use	of	CRISPR	in	the	
sickle-cell	anemia	case	study	is	just	one	potential	application	of	this	versatile	
technology.	So	in	addition	to	improving	CRISPR’s	safety,	ethical	guidelines	that	address	
how	we	will	use	CRISPR	is	also	necessary	to	ensure	responsible	applications	of	it.		
	
Convergence	of	Science	and	Business	
	
	 The	commercialization	of	the	Flavr	Savr	tomato	involved	certain	areas	of	
contention	between	the	Calgene	scientists	and	its	business	executives:	the	lack	of	
communication,	the	culture	clash	between	management	and	scientists,	and	the	lack	of	
business	expertise.	In	the	late	1980s,	Calgene	was	a	science-based	company	that	
wanted	to	enter	the	fresh	tomato	business	by	itself,	but	the	company	and	the	Flavr	Savr	
tomato’s	eventual	demise	was	due	to	Calgene’s	inability	to	manage	the	expenses	
associated	with	commercializing	the	tomato.	There	was	not	an	issue	behind	the	science	
that	created	the	Flavr	Savr	tomato.43		
																																																						
43	Martineau,	B.	(2001).	First	Fruit:	The	Creation	of	the	Flavr	Savr	Tomato	and	the	Birth	
of	Genetically	Engineered	Food.	London:	McGraw-Hill.	
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	 Today,	more	academic	institutions	are	becoming	involved	in	commercializing	the	
CRISPR	technology	by	creating	biotechnology	companies	invested	in	exploiting	this	
technology.	Equipped	with	the	scientific	knowledge	of	working	with	CRISPR,	academic	
institutions	collaborate	with	business	professionals,	who	have	the	knowledge	to	help	
move	the	technology	onto	the	market,	to	establish	biotechnology	companies.	As	a	
result,	scientists	and	business	professionals	and	their	differences	in	work	culture	and	
style	will	be	intersecting	more	frequently.	Reflecting	on	the	lessons	from	the	contention	
between	Calgene’s	scientists	and	management	that	contributed	to	the	company’s	
inefficient	commercialization	operations,	we	can	observe	that	if	the	differences	
between	science	and	business	are	not	being	addressed,	both	scientists	and	business	
professionals,	respectively,	will	be	working	inefficiently	alone	while	attempting	to	bring	
CRISPR	to	consumers	together.	
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Conclusion	
	
CRISPR’s	emergence	as	a	new	genome-editing	technology	has	resulted	in	a	
fivefold	increase	in	investments	in	the	genome-editing	market	over	the	past	year.	
Additionally,	in	2015,	several	CRISPR	biotechnology	companies,	including	CRISPR	
Therapeutics	and	Editas	Medicine,	received	$550	million	in	investments.	This	
investment	was	a	twofold	increase	of	2013	and	2014’s	aggregate	investments.6	From	
these	facts,	we	can	comprehend	how	plans	to	commercialize	CRISPR	appear	to	be	
inevitable.	CRISPR	has	been	lauded	for	its	ease	of	use,	remarkable	precision,	and	relative	
low	cost	to	other	genome-editing	technologies	like	zinc-finger	nucleases	(ZFNs).	These	
promising	characteristics	of	CRISPR	are	disrupting	the	way	researchers	conduct	
research,	shortening	experiment	times,	and	consequently	increasing	efficiency.	With	
CRISPR’s	customizable,	relatively	precise	targeting	system	to	edit	genomes,	scientists	
are	optimistic	that	this	technology	can	be	utilized	in	a	wide	range	of	applications.		
Commercialization	of	CRISPR	largely	depends	on	the	collaboration	between	
science	and	business.	Addressing	the	legal	and	ethical	considerations	are	important	to	
ensure	that	commercialization	can	occur.	However,	the	process	of	commercialization	
directly	involves	scientists	and	business	professionals.	The	simplified	commercialization	
process	involves	scientists	working	with	CRISPR	in	the	lab	and	business	professionals	
marketing	and	selling	CRISPR	applications	on	the	market.	When	academic	institutions	
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plan	on	commercializing	CRISPR,	scientists	often	cannot	commercialize	it	on	their	own;	
scientists	seek	to	collaborate	with	people	in	business	who	may	have	more	resources	and	
expertise	in	making	the	transition	from	lab	to	market	smoother.	Therefore,	for	academic	
institutions	to	commercialize	genome-editing	technologies	like	CRISPR,	it	is	important	to	
ensure	there	is	minimal	language	and	culture	disconnect	between	science	and	business	
that	could	make	the	commercialization	process	more	inefficient.			
To	work	towards	bridging	any	disconnect,	we	should	aim	to	continue	promoting	
open,	ongoing	conversations	among	scientists,	ethicists,	and	the	general	public	about	
the	risks	and	benefits	of	CRISPR	and	about	the	commercial	considerations	of	this	
technology.	In	contrast	to	the	time	of	the	1975	Asilomar	conference	when	most	
scientists	who	conducted	recombinant	DNA	research	worked	in	public	institutions,	
today	many	scientists	are	also	working	in	private	companies	and	the	issues	are	wider	
and	more	complex	in	scope,	involving	the	safety	of	CRISPR,	the	ethics	of	its	use	in	
germline	editing,	the	legal	consequences	of	the	CRISPR	patent	dispute,	inter	alia.		
At	the	time	of	the	Asilomar	conference,	scientists	worked	in	public	institutions	
when	government	funding	for	research	was	not	as	limited	and	the	competition	for	
grants	was	not	as	intense	as	they	are	today.44	As	a	result,	scientists	were	able	to	freely	
express	their	opinions	about	recombinant	DNA	technology	without	being	concerned	
																																																						
44	Howard,	D.	J.,	&	Laird,	F.	N.	(2013).	The	New	Normal	in	Funding	University	
Science.	Issues	in	Science	and	Technology,	(1).		
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that	their	opinions	might	affect	the	amount	of	research	funding	they	could	attain.	Now,	
with	more	scientists	working	at	private	companies,	scientists	are	more	focused	on	the	
commercial	opportunities	of	genome-editing	technologies.	With	reduced	allocation	of	
the	federal	budget	to	research	and	development,	locating	funding	becomes	paramount.	
However,	scientists	today	are	increasingly	more	cautious	about	disclosing	their	opinions	
on	these	technologies	or	communicating	the	technologies’	risks,	because	being	
transparent	about	potential	risks	may	make	attaining	funding	more	difficult.		
Conferences,	such	as	the	2015	International	Summit	on	Human	Gene	Editing,	
where	scientists	and	nonscientists	worldwide	gather	to	exchange	their	respective	
concerns	and	questions	about	the	applications	of	genome-editing	technologies,	should	
continue	to	be	hosted.	There	are	potential	challenges	and	questions	that	should	be	
considered	with	hosting	these	international	discussions	across	countries	and	cultures,	
including	the	feasibility	of	organizing	a	large-scale	conference	on	a	more	frequent	basis	
or	whether	we	can	even	formulate	a	general	consensus	among	the	diversity	of	opinions.	
Having	scholars	from	other	disciplines	like	the	social	sciences	and	business	participate	
and	express	their	viewpoints	in	these	conferences	can	better	reflect	the	nuanced	
interests	of	the	general	public.45	Although	it	may	be	premature	to	assign	a	value	to	the	
effectiveness	of	an	international	conference	just	based	on	our	experience	from	the	2015	
																																																						
45	Addison,	Courtney,	and	Samuel	Taylor-Alexander.	"Gene	Editing	and	Germ-line	
Intervention:	The	Need	for	Novel	Responses	to	Novel	Technologies."	Molecular	
Therapy	23.11	(2015):	1678-680.	Web.	
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summit,	having	an	open	setting	where	conference	participants	can	view	all	the	potential	
situations	involving	the	use	of	these	technologies	and	have	the	opportunity	to	grapple	
with	those	situations	can	begin	to	foster	more	public	trust	in	how	scientists	and	policy	
makers	are	approaching	this	issue	of	using	genome-editing	technologies	responsibly.	
With	a	range	of	stakeholders	involved	in	the	discussion	on	the	use	of	CRISPR	and	other	
genome-editing	technologies,	stakeholders	can	reflect	on	issues	from	others’	
perspectives	and	possibly	achieve	greater	understanding	for	others’	viewpoints.46	
Within	science-based	businesses	developed	from	academic	institutions,	for	
example	the	creation	of	Caribou	Biosciences	from	UC	Berkeley,	collaboration	between	
scientists	and	business	professionals	is	inevitable	–	since	these	scientists	aim	to	develop	
their	research	in	CRISPR	and	other	genome-editing	technologies	to	benefit	others,	
scientists	are	partly	responsible	to	inform	and	engage	the	general	public	about	their	
research.47	For	scientists	to	achieve	their	goal	of	transitioning	CRISPR	from	the	lab	to	the	
market,	they	must	also	do	their	best	to	understand	how	business	professionals,	who	
provide	their	business	acumen	and	knowledge	of	marketing	and	selling	the	technology,	
work.		
Business	professionals	value	implementing	strong	organizational	culture	in	their	
work	places	to	encourage	strong	working	relationships	and	efficiency,	promoting	
																																																						
46	Jensen,	K.	K.,	Forsberg,	E.,	Gamborg,	C.,	Millar,	K.,	&	Sandøe,	P.	(2010,	June	30).	
Facilitating	Ethical	Reflection	Among	Scientists	Using	the	Ethical	Matrix.		
47	"Public	Dialogue	on	Genome	Editing:	Why?	When?	Who?"	(2016):	n.	pag.	Web.	
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specific	company	values	and	management	practices.	These	business	practices	might	be	
more	unfamiliar	to	scientists,	who	are	seen	as	more	focused	on	making	discoveries	from	
their	research.	Business	professionals	should	also	strive	to	consider	scientists’	opinions	
about	commercializing	CRISPR	and	maintain	clear	communication	with	and	provide	
regular	updates	to	scientists	throughout	the	entire	commercialization	process.	Although	
business	professionals	are	tasked	with	moving	the	commercialization	process	of	the	
technology	forward,	scientists	are	the	ones	who	are	most	knowledgeable	about	how	the	
technology	works,	its	technical	risks	and	benefits,	and	how	its	mechanisms	can	be	
applied	into	practical	products	for	the	public.		
The	general	public	are	the	end	users	of	applications	developed	using	genome-
editing	technologies.	So,	as	a	measure	of	encouraging	transparent	conversation	about	
genome	editing	and	the	use	of	genome-editing	technologies,	it	is	critical	to	listen	to	the	
voices	of	the	public.	Studies	have	shown	that	many	of	the	terms,	such	as	“gene”	and	
“genetics”,	discussed	in	debates	on	genome	editing	are	unfamiliar	to	the	public.48	
Developing	community	programs	or	forums	can	aid	in	providing	the	public	with	
resources	to	learn	more	about	basic	jargon	used	in	discussing	genome	editing.	In	
informal,	familiar	settings,	these	forums	can	give	individuals	the	opportunity	to	listen	
and	relate	to	the	concerns	of	other	community	members.	Program	moderators	could	be	
																																																						
48	Blendon,	Robert	J.,	Mary	T.	Gorski,	and	John	M.	Benson.	"The	Public	and	the	Gene-
Editing	Revolution."	New	England	Journal	of	Medicine	374.15	(2016):	1406-411.	Web.	
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researchers	in	the	community	or	representatives	from	science	advisory	groups	like	the	
National	Academy	of	Sciences	that	have	the	resources	and	knowledge	to	inform	
community	members	about	the	uses	of	CRISPR	and	to	respond	to	the	public’s	questions.	
Moderators	may	have	roles	in	science	policy	making,	so	they	should	identify	and	record	
community	members’	main	concerns	that	will	be	taken	into	consideration	when	making	
policies	to	determine	how	we	should	proceed	in	using	CRISPR.		
Opening	up	conversation	to	include	all	stakeholders,	not	just	to	scientists	and	
business	professionals,	can	expand	our	intellectual	resources	to	be	available	to	
everyone.	As	we	continue	to	learn	more	about	CRISPR’s	mechanisms,	make	progress	in	
sharpening	CRISPR’s	cuts,	and	observe	the	evolving	field	of	gene	editing,	encouraging	
ongoing	discussion	can	equip	us	with	up-to-date	intellectual	resources	needed	to	help	
address	future	concerns	about	commercializing	genome-editing	technologies.		
Ethics	training	for	both	scientists	and	business	professionals	should	also	be	
provided.	Scientists	participate	in	ethics	training	when	they	are	in	school	and	business	
professionals	often	undergo	ethics	training	at	their	workplaces,	but	in	the	specific	case	
of	commercializing	genome-editing	technologies	like	CRISPR,	which	can	have	significant	
implications	if	not	used	responsibly,	it	is	crucial	to	organize	specialized	trainings.	
Genome-editing	advisory	groups	and	ethics	councils,	comprised	of	experts	with	
backgrounds	in	ethics	and	research,	from	academic	institutions	should	organize	these	
CRISPR	ethics	trainings.	Scientists	who	attend	these	trainings	have	the	opportunity	to	
	 66	
reflect	upon	and	discuss	the	potential	ethical	implications	of	their	research	with	other	
scientists.	These	trainings	should	also	aim	to	teach	scientists	methods	on	how	they	can	
clearly	communicate	accurate	information	about	and	the	ethical	implications	of	CRISPR	
to	nonscientists.		
Business	professionals	would	also	benefit	from	attending	ethics	trainings	that	
inform	participants	on	what	the	general	risks	of	CRISPR	are,	not	delving	into	the	
technical	challenges,	so	that	these	professionals	can	comprehend	the	importance	of	
making	ethical	decisions	throughout	the	commercialization	process.	Also,	the	ethics	
trainings	should	discuss	ways	by	which	business	professionals	can	help	scientists	
communicate	the	ethical	uses	of	CRISPR.	Business	professionals	are	coming	from	the	
perspective	of	a	nonscientific	group,	so	these	professionals	can	provide	insights	to	
scientists	about	how	to	more	effectively	communicate	with	nonscientists.		
Due	to	different	individuals’	opinions	about	what	ethics	topics	are	considered	
most	critical	for	scientists	and	business	professionals	to	learn,	there	may	be	
disagreement	among	ethics	councils	and	genome-editing	advisory	groups	on	deciding	
what	content	the	ethics	trainings	should	cover.	The	ethics	councils	and	advisory	groups	
should	seek	to	find	common	ground	on	the	most	salient	ethics	topics	that	the	majority	
of	the	individuals	believe	must	be	addressed	in	the	trainings.	Just	as	ethical	guidelines	
that	provide	general	directions	on	how	we	should	proceed	with	the	use	of	CRISPR	are	
	 67	
difficult	to	develop,	determining	the	content	of	ethics	trainings	for	scientists	and	
business	professionals	is	challenging	to	implement,	too.		
The	advances	in	genome	editing	and	genome-editing	technology	are	innovative	
and	changing	how	scientists	conduct	research,	how	business	professionals	are	choosing	
to	invest	in	life-science	companies,	and	how	the	general	public	approaches	disease,	
human	health,	and	the	ways	in	which	we	live	our	lives.	With	the	introduction	of	CRISPR,	
the	field	of	genome-editing	technology	is	living	through	a	time	when	we	have	a	“higher	
threshold	for	trying	something	risky	because	the	benefit	could	be	so	remarkable.”49		
	
	
	
	
	
	
	
	
	
	
																																																						
49	New	Gene-Editing	Techniques	Hold	the	Promise	of	Altering	the	Fundamentals	Of	Life.	
(2017,	January	12).		
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